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ABSTRACT 
 
ELIZABETH MARIE MANDEL:  Molecular Mechanisms of Tbx20 Regulation 
 
(Under the direction of Dr. Frank L. Conlon) 
 
 
 The proper formation of the vertebrate heart involves the orchestration of many 
complex processes including induction, commitment, cell migration and morphogenesis.  
Each of these events is controlled by regulated gene expression within multiple 
transcriptional regulatory networks in a spatially and temporally restricted manner, and only 
slight changes in gene expression can lead to severe cardiac anomalies.  One key example is 
provided by the T-box transcription factor, TBX20.  Homologs of Tbx20 have been described 
in a variety of organisms including mouse, zebrafish, chick, Xenopus and human, and with 
Nkx2.5 and Tbx5, it is one of the earliest markers of cardiac tissue.  Analyses of TBX20 
knockdown in mouse and Xenopus have also demonstrated a requirement for TBX20 in early 
heart development through an involvement in morphogenesis, cell proliferation and 
transcriptional regulation.  However, the mechanisms controlling the tissue-specific 
regulation of Tbx20 have yet to be described.  Recently, both missense and nonsense 
mutations within the DNA-binding domain of human TBX20 have been shown to result in 
diverse cardiac pathologies including septal defects, valve defects, and cardiomyopathy.  In 
an effort to clearly define the origins of such congenital heart defects, it will therefore be 
necessary to fully understand the transcriptional regulation and localized expression of genes 
such as Tbx20, that are involved in the earliest stages of cardiac development.   
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To this end, the work described here focuses on the characterization of Tbx20 
transcriptional regulation in the developing heart.  We first demonstrate that the sequence and 
expression patterns of multiple T-box genes, including Tbx20, are conserved across species, 
including in the diploid frog Xenopus tropicalis (X. tropicalis).  Our studies next go on to 
show that Tbx20, unlike other cardiac genes described to date, is expressed throughout all 
regions of the developing heart including both myocardial and endocardial layers.  Utilizing 
transgenesis in both Xenopus and zebrafish, we have identified and characterized a conserved 
334bp regulatory element that is sufficient to drive expression of Tbx20 throughout these 
regions of the heart.  To compliment these studies, we have also demonstrated a role for the 
BMP signaling pathway in the regulation of Tbx20, whereby the downstream BMP mediator 
SMAD1 directly binds regions within the cardiac regulatory element to drive gene expression 
in a dose-dependent fashion.  This is the first evidence for a role of specific signaling 
pathways in the regulation of Tbx20 expression, and provides key insights into the 
transcriptional regulatory network that is responsible for proper cardiac development. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
 Congenital heart defects (CHDs) threaten nearly 1% of all newborns and pose as a 
significant threat of infant death; however, the underlying genetic mechanisms of many 
CHDs remain elusive.  Most likely, the majority of these defects have a basis in the complex 
process of cardiogenesis.  Heart development is a progression of highly coordinated events 
including cell proliferation, differentiation, migration and morphogenesis, and it is likely that 
the alteration in expression of genes involved in these processes underlies a variety of 
cardiovascular defects.  Therefore, by better understanding the molecular and cellular 
processes involved in normal heart development, we will gain insight into the origin of 
CHDs.  To this end, a number of genes have been identified as potential causes of specific 
cardiac anomalies.  For example, T-box genes, such as Tbx1, Tbx5 are associated with 
congenital heart defects in humans in affiliation with DiGeorge syndrome and Holt-Oram 
syndrome phenotypes, respectively.   Additionally, Tbx20, another member of the T-box 
gene family, has recently been linked to human congenital heart disease as nonsense or 
missense mutations in the genomic locus result in a complex spectrum of cardiovascular 
defects.  In an effort to further understand its function and significance, Tbx20 has been 
cloned and its expression characterized in numerous models, including Xenopus.  Along with 
Nkx2.5 and Tbx5, Tbx20 is one of the earliest markers of heart tissue in Xenopus and appears 
  2 
to play important roles in early heart development in a variety of organisms.  However, the 
regulation and transcriptional regulatory functions of Tbx20 have yet to be described.  
 
Xenopus as a model system for studies of early heart development 
Supported by over one hundred years of experimental embryology in amphibians, 
Xenopus is a well-established and outstanding model in which to study early organogenesis 
(67).  Xenopus embryos are large, easily manipulated and easily obtained in large numbers.  
In addition, a well established fate map of embryos beginning at the gastrula stage allows for 
the identification of cells which will give rise to the heart as early as the 32-cell stage (16, 
37).  As Xenopus embryos are non-placental, and raised in liquid media, early development 
can proceed even in the absence of a functional circulatory system, allowing for a more 
detailed analysis of the mechanisms of early cardiovascular development.  Although there are 
significant differences between the anatomy of adult amphibian and human hearts, it appears 
that many of the molecular and cellular processes involved in early heart development are 
conserved (5, 13, 67).   
In addition, the use of the diploid frog, Xenopus tropicalis (X. tropicalis), has recently 
made genetic analysis feasible.  These frogs reach sexual maturity in as little as 6 months, 
and can be utilized in both embryological and genetic studies.  Additionally, the X. tropicalis 
genome has been fully sequenced, partially annotated and is publicly available (Joint 
Genome Institute, U.S. Department of Energy).  In combination with the well established 
Xenopus laevis (X. laevis) system, the X. tropicalis system will be a very important tool in 
studies of the specification of cardiac precursor cells and early development (55, 67). 
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Early Vertebrate Heart Development   
Morphogenesis 
In vertebrates, the heart represents the first functioning organ.  During early 
embryogenesis, heart precursors originate from bilateral patches of cells in the anterior lateral 
plate mesoderm that include populations of both myocardial and endocardial cells (15, 62).  
These cells are specified to the cardiac lineage during the process of gastrulation (3, 50).  The 
two populations of cells subsequently migrate anteriorly and ventrally until they fuse at the 
ventral midline to form a single heart field known as the cardiac crescent (18, 48).  It is at 
this point the precursors begin to express the first markers of cardiac development and 
differentiation, such as the T-box transcription factor Tbx5, the homolog of Drosophila 
tinman, Nkx2.5, and the transcription factor mef2 (10, 17, 63).  With the fusion of the two 
precursor populations into the cardiac crescent, the cardiac cells are arranged into the 
primitive linear heart tube which then undergoes a process of rightward and dorsal looping to 
bring the future chambers into the correct alignment (22, 36, 69).  This initial cardiac 
crescent, termed the primary heart field, however, has been shown to account for the majority 
of the total endocardial and myocardial progenitor cells of the adult heart, but not all.  
Additional populations of cardiac precursors derived from the splanchnic mesoderm and 
cranial mesoderm, termed the secondary and anterior heartfields, respectively, contribute to 
the conotruncal myocardium, right ventricle and outflow tract of the developing heart during 
the process of cardiac looping (27, 35, 66).   Following the integration of each of these 
cardiac progenitor populations, and as embryogenesis proceeds, the cardiac chambers begin 
to mature and are finally septated to produce the fully functioning heart (6).  
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Signaling 
 The complex patterns of cell migration and morphogenesis, which result in the 
formation of a multi-chambered, beating heart, have been shown to be regulated by a number 
of secreted factors and signaling pathways originating from the endoderm and the organizer, 
or node (26, 39, 49).  While the exact nature of these secreted signals has yet to be 
elucidated, a variety of studies have demonstrated roles for molecules such as BMP/TGF-βs, 
the Wnt antagonists Dkk-1 and Crescent, Notch, and fibroblast growth factors (FGFs) (69).  
The strongest evidence for a role of BMP molecules in vertebrate heart development comes 
from studies in chick, frog and mouse.  For example, ectopic application of BMP-2 or 4 in 
chick leads to ectopic expression of cardiac-specific transcription factors such as Nkx2.5 (52), 
while activin, a member of the BMP family, has the ability to induce heart tissue  in 
ectodermal explants in Xenopus laevis (30).  While BMP signals from the endoderm are 
necessary for proper heart formation, they are not sufficient.  Work in chick and frog 
demonstrates a requirement for the inhibition of canonical Wnt3A and Wnt8 signals in the 
mesoderm through the diffusion of Dkk and Crescent (33, 51, 65).  Additionally, 
cardiogenesis in Xenopus can be stimulated through non-canonical Wnt11 signaling, 
suggesting the necessity of an intricate network of Wnt signals (42).  Notch signaling has 
also been shown to play an inhibitory role in heart development; however, its actions appear 
to be downstream of heart field specification.  Xenopus studies reveal that upregulation of 
Notch signaling results in an inhibition of myocardial differentiation, while Notch 
inactivation leads to ectopic expression of myocardial markers (46).  A variety of studies 
have also implied a role for members of the FGF family at numerous stages of cardiac 
development.  The strongest evidence in vertebrates comes from studies of Fgf8 in zebrafish 
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and mouse.  Zebrafish homozygous for mutations in Fgf8 (acerebellar, or ace) fail to turn on 
markers of early heart development (45) and disruption of Fgf8 in mouse results in defects in 
cardiac looping and abnormal cardiovascular patterning (1, 64).  Unlike BMP signaling, 
however, it appears that FGFs are only transiently required. 
 
Transcription factor response to inductive signals 
In combination with these inductive signals from the endoderm and organizer, a 
number of regulatory genes encoding a series of transcription factors are induced and act in 
the processes of specification, patterning and differentiation of the heart.  One of the most 
well-defined examples, the homeobox gene Nkx2.5, a vertebrate homolog of the Drosophila 
gene tinman, is expressed in the lateral plate mesoderm coinciding with the time and place of 
cardiac specification.  Genetic studies in a variety of organisms have demonstrated that 
Nkx2.5 functions at many stages of cardiac development [reviewed in (21, 23)].  Complete 
loss of Nkx2.5 in mouse results in early embryonic lethality with severe cardiac defects, 
while mutant alleles of Nkx2.5 correlate to inherited atrial-septal defects in humans (31, 32).  
Recently, Nkx2.5 has been shown to orchestrate a Smad1-dependent negative feedback loop 
that acts to control heart progenitor specification and proliferation (44).  Generally, Nkx2.5 
acts to repress BMP2 signaling via Smad1 in the secondary heart field (SHF), while itself is 
upregulated by active Smad1 signaling in the SHF and foregut endoderm.  Active Nkx2.5 in 
the SHF leads to continued proliferation of cardiac precursors, whereas active BMP signaling 
through phosphorylated Smad1 leads to the induction of cardiac progenitor genes and a block 
of proliferation (44).  Through this autoregulatory loop, Nkx2.5 is key in the transition 
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between periods of cardiac induction and progenitor proliferation (44).  In addition, it 
emphasizes the importance of BMP signaling in the proper development of the heart. 
Another factor, Gata4, encodes a zinc-finger transcription factor essential for 
cardiogenesis and directly interacts with Nkx2.5 and TBX5 to synergistically activate cardiac 
gene expression (9, 20).  Haploinsufficiency of GATA4 has been linked to congenital septal 
defects in humans likely due to reduced DNA binding and transactivation of target genes, as 
well as loss of TBX5 interactions (19, 32, 41, 43). 
 
T-box genes in early cardiogenesis 
A large body of evidence supports a role for a number of members of the T-box 
family of transcription factors in early heart development.  Members of the T-box family are 
characterized by a 180 amino acid, evolutionarily conserved T-box DNA binding domain and 
have been shown to play important and diverse roles in embryonic development, including 
germ layer differentiation and organogenesis (47, 57, 68).  In support of these family 
members playing key roles in cardiogenesis, studies have shown these genes to have the 
ability to respond to mesodermal growth factors such as FGF and TGF-β family members 
(53, 57).  Additionally, mutations in three T-box genes, Tbx1 (4), Tbx5 (38), and Tbx20 (28) 
have been connected to the clinical manifestation of congenital heart defects in humans (32).  
Patients presenting with the DiGeorge syndrome phenotype carry either deletions or 
mutations in the Tbx1 gene (4, 14), while over 30 different mutations in Tbx5 have been 
described in Holt-Oram syndrome patients (24, 38).  It was not until recently, however, that 
one missense and one nonsense mutation were found to be associated with a family history of 
CHD and a wide spectrum of developmental defects (28).  For these reasons, it will be 
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important to further characterize the roles of these, and other, T-box genes in the complex 
processes of early cardiogenesis. 
 
Tbx20 and heart development  
With Tbx5 and Nkx2.5, Tbx20 has been shown to be one of the earliest genes 
expressed in the vertebrate cardiac lineage.  Tbx20 homologs have been described in a 
variety of organisms including mouse (Tbx12/20) (12, 29), zebrafish (Tbx20/HrT) (2), chick 
(26), Xenopus (7) and human (34).  In Xenopus, Tbx20 is first expressed in gastrula stage 
embryos in the ventral half of the cement gland.  As development proceeds, expression is 
seen in the migrating heart precursors in concert with the earliest markers of cardiac 
development, Nkx2.5 (40) and Tbx5 (25, 54).  Eventually, Tbx20 can be visualized in all 
regions of the heart including the atria, ventricles, inflow and outflow tracts and the septum 
transversum (7, 54).  In addition to the heart, Tbx20 expression is also present in the external 
jugular vein, lung bud, cloacal aperture, rhombomeres, and a subset of motor neurons (7, 54). 
 Tbx20 has been shown to be required for proper cardiogenesis in zebrafish, Xenopus 
laevis, mouse and human (8, 11, 28, 56, 59-61).  Using morpholino oligonucleotides, Szeto 
and colleagues demonstrated that zebrafish embryos lacking functional hrT, the zebrafish 
homolog of Tbx20, have abnormal hearts and a lack of blood circulation.  It appears that 
early events of heart formation are unaffected, while hearts fail to undergo looping at later 
stages (60).  Studies in Xenopus, also using morpholinos, reveal that embryos lacking TBX20 
display severe cardiac defects such as an unlooped heart, reduced cardiac mass, and 
pericardial edema (8).  To further the understanding of TBX20 function, multiple groups 
have gone on to characterize the effects of TBX20 knock-down in the mammalian system.  
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Embryos with reduced levels of TBX20 by means of transgenic RNA interference or gene 
targeting are characterized by severe cardiac abnormalities such as outflow tract and right 
ventricular hypoplasia, disruptions in the early cardiac transcriptional program, and early 
embryonic lethality (11, 56, 59, 61).  In addition, a number of groups have shown that Tbx20 
null embryos exhibit ectopic expression of the T-box gene Tbx2, which plays a key role in 
the repression of chamber differentiation, thus suggesting that TBX20 acts as a 
transcriptional repressor during early heart development (56, 59).  TBX20 has also been 
shown to interact with a number of other transcription factors in regulating cardiac gene 
expression.  Stennard and colleagues have demonstrated in Xenopus that TBX20 interacts 
with Nkx2.5, GATA4, and GATA5 to synergistically act on cardiac promoters such as 
Nppa/ANF (atrial natriuretic factor) (58).  Additionally, Brown et al. have shown that TBX20 
physically and functionally interacts with TBX5 to control Xenopus heart morphogenesis, 
thus providing the first evidence for direct interactions between T-box family members (8).   
 
DISSERTATION GOALS 
Even with these recent studies, the precise regulation, molecular functions or cellular 
requirements for Tbx20, or any one T-box family member, remain elusive.  In fact, it is one 
of the necessities in the field of cardiovascular development to fully dissect the main 
transcriptional pathways that govern development and to understand how disruptions of the 
genes that encode components of these pathways lead to aberrations in proper development.  
To this end, my work focuses on exploring the precise expression and transcriptional 
regulation of Tbx20 in the heart and to place it into the larger transcriptional regulatory 
network that governs early cardiac development.  Initially, I focus on a detailed 
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characterization and comparison of Tbx20 expression, in addition to the T-box transcription 
factors Tbx1, Tbx2, and Tbx5, in X. laevis and X. tropicalis.  I go on to describe the 
identification of a cardiac-specific regulatory element that is necessary for proper Tbx20 
expression, and finally, place Tbx20 regulation in the context of two major signaling 
cascades, that of bone morphogenetic protein (BMP) and that of serum response factor 
(SRF).  This is the first description of the regulatory networks controlling the temporal and 
spatial regulation of Tbx20. 
In a similar manner, a further understanding of the molecular mechanisms that control 
cellular proliferation and differentiation is a central theme in developmental biology, and has 
direct relevance to our studies of cardiac development.  Therefore, in addition to my studies 
examining Tbx20 regulation, I also describe the first characterization of the transcriptional 
regulation and differential roles of two co-transcribed microRNAs, miRNA-1 and miRNA-
133, in skeletal muscle proliferation and differentiation.  This work is a clear demonstration 
how additional signaling factors, such as miRNAs, can participate in, and have key roles in 
the transcriptional networks that control early developmental events. 
Generally, it is my hope that by fully characterizing the expression and regulation of 
the Tbx20 gene in Xenopus, and by beginning to define the molecular mechanisms that 
control the expression of additional regulatory factors, it may be possible to gain a clearer 
picture of the molecular mechanisms governing heart development and to in turn, better 
understand the congenital heart defects resulting from aberrations in this process. 
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CHAPTER 2 
 
TRANSCRIPTIONAL MECHANISMS OF CONGENITAL  
HEART DISEASE 
 
 
 
PREFACE 
 Chapter 2 focuses on the current understanding of the transcription factors that have 
been linked to familial congenital heart diseases.  This work was published, in part, as a 
review article, and represents a first-author manuscript and collaboration with Thomas E. 
Callis and Da-Zhi Wang.  At the time of publication, mutations or deletions of the 
transcription factors Tbx1, Nkx2.5, Gata4, Tbx5, Sall1, TFAP2B, and Eya4 had been 
associated with human disease.  Since that time, however, missense and nonsense mutations 
in the cardiac transcription factor Tbx20 have been linked to a variety of congenital heart 
defects.  This emphasizes the rapid pace at which the fields of cardiac development and 
disease are advancing, and further supports the need for continuing research in these areas. 
 
Mandel, E.M., T.E. Callis, D.Z. Wang, and F.L. Conlon.  2005.  Transcriptional 
mechanisms of congenital heart disease.  Drug Discovery Today:  Disease 
Mechanisms 2(1):33-38. 
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SUMMARY 
Over the past decade, clinical studies have identified a number of congenital 
heart diseases associated with mutations in cardiac transcription factors.  Recent 
reports have shown that several of these transcription factors physically interact with 
one another, implying they may act in similar molecular pathways.  Here, we outline 
familial heart diseases linked to cardiac transcription factors and describe some of the 
emerging technologies being developed as potential therapeutics for these diseases. 
 
INTRODUCTION 
 Congenital heart defects (CHDs) threaten nearly 1% of all newborns and pose a 
significant threat of infant death; however, the underlying genetic mechanisms of many 
CHDs remain elusive.  Most likely, the majority of these defects have a basis in the complex 
process of cardiogenesis.  Heart development involves a series of highly coordinated events 
including cell proliferation, differentiation, migration and morphogenesis, and a number of 
genes involved in these processes have been identified as potential causes of specific cardiac 
anomalies.  Transcription factors are major regulators of developmental processes and play 
essential roles in cardiogenesis (Fig. 2.1).  Here, we review 6 CHDs associated with deletions 
or mutations of transcription factors and the current understanding of their molecular bases. 
 
DiGeorge Syndrome:  Tbx1 
The presentation of DiGeorge syndrome (OMIM #188400) is one consequence of the 
most common human genetic deletion, monoallelic microdeletion (see glossary) of 
chromosome 22q11.2.  In most cases, the heterozygous deletion eliminates approximately 
 18 
3Mbp of the long arm of chromosome 22, resulting in the loss of an estimated 30 genes (3).  
Recent studies have described highly variable clinical indications of patients with 
chromosome 22q11.2 deletions, even within the same pedigree.  However, CHDs are the 
most common feature of DiGeorge syndrome, or del22q11, and may include tetralogy of 
Fallot, interruption of the aortic arch type B, ventricular septal defects, pulmonary atresia, or 
persistent truncus ateriosus (see glossary for terms; Fig. 2.2) (3, 51). 
 The use of mouse genetics has recently clarified which of the numerous genes deleted 
in del22q11 may be responsible for the DiGeorge syndrome phenotypes.  Targeted mutations 
in the mouse genome have allowed the majority of the DiGeorge syndrome clinical 
manifestations to be attributed to haploinsufficiency of Tbx1 (AF012130), one of the genes 
deleted in del22q11 patients (3, 15).  Tbx1 is a member of the T-box family of transcription 
factors and is involved in the patterning of the pharyngeal endoderm and aortic arches, as 
well as cardiac outflow tract development in a gene dosage-dependent manner (51).  
Attempts to further connect Tbx1 to DiGeorge syndrome have led to searches for mutations 
in this gene in patients lacking the typical chromosomal deletion.  To this end, five patients 
have been identified as carrying only a Tbx1 gene mutation (50).  Though these individuals 
do not exhibit all characteristics of DiGeorge syndrome, this demonstrates that mutations in 
human Tbx1, as in mouse, are capable of causing many of the defects associated with 
del22q11.  In an effort to understand the molecular mechanisms of TBX1 function, recent 
observations have resulted in a model in which Fgf8 in the pharyngeal endoderm is regulated 
by TBX1 to control the proper patterning of the aortic arch through epithelial-mesenchymal 
interactions (Table 2.1) (51).  Additionally, Tbx1 transcription has been shown to be 
regulated by the sonic hedgehog (shh) signaling pathway via the Foxc1 and Foxc2 
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transcription factors which are expressed in the head mesenchyme and the mesenchyme 
surrounding the aortic arch arteries (Table 2.1) (51).  Together, studies such as these 
demonstrate signaling cascades by which Tbx1 is transcribed and may initiate proper 
patterning events; however, the complete mechanism of TBX1 action remains unknown. 
 
Familial Cardiac Septal Defects: Nkx2.5, Gata4 and Tbx20 
Cardiac septal defects (CSDs) are a common form of CHD and are defined by a hole 
in the septal wall allowing blood transfer between the atria or ventricles.  Atrial septal defects 
(ASDs) affect over one in 1000 live births, while ventricular septal defects (VSDs) are the 
most prevalent CHD, occurring in approximately one in 300 live births (Fig. 2.2).  Over time, 
persistent left-to-right shunting of blood between the atria or ventricles leads to pulmonary 
hypertension, arrhythmias, and atrial and ventricular dysfunction.  Fortunately, severe ASDs 
and VSDs can be treated by surgical- or catheter-based procedures that employ a prosthetic 
patch to close the defect.  Despite the high incidence of CSDs, the precise molecular 
mechanisms directing septal morphogenesis remain unclear.  However, genetic studies have 
implicated mutations in the Nkx2.5 and Gata4 loci as genetic causes of familial CSDs. 
Mutant alleles of the Nkx2.5 locus (BC025711) correlate with ASDs in rare families 
in which the defect is inherited (Fig. 2.2) (44).  Genetic studies in a wide variety of 
organisms demonstrate that NKX2.5 functions at many stages of cardiac development and in 
a variety of cardiac tissues (18, 19).  Complete loss of NKX2.5 in mice results in early 
embryonic lethality with severe cardiac defects (30), while mice heterozygous for the Nkx2.5 
allele only occasionally suffer ASDs (5).  This suggests that genetic modifiers are important 
for ASD penetrance.  NKX2.5 interacts with other transcription factors associated with 
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CHDs such as GATA4 and TBX5, and many cardiac-specific genes contain NKX2.5 binding 
sites in their promoters, highlighting the importance of Nkx2.5 in the cardiac transcriptional 
program (Table 2.1) (12).  Chien et al. (2004) reported that mice harboring a ventricular 
muscle-cell restricted knockout of Nkx2.5 mimic CHD and implicated persistent BMP-10 
(Bone Morphogenetic Protein-10) expression as playing an important role in the onset and 
progression of observed cardiac defects (39).  This study suggests that antagonizing BMP-10 
signals could represent a new therapeutic approach to prevent progression of Nkx2.5-
associated CHDs.  
ASDs, as well as VSDs and atrioventricular septal defects, are also associated with 
Gata4 (AY740706) haploinsufficiency (Fig. 2.2) (16, 36, 40).  A study of a large pedigree 
revealed a missense mutation in Gata4 linked to an autosomal dominant disorder where ASD 
was fully penetrant.  Gata4 encodes a zinc-finger transcription factor essential for 
cardiogenesis, and directly interacts with the cardiac transcription factors NKX2.5 and TBX5 
to synergistically activate cardiac gene expression (12, 17).  Inherited mutations in Gata4 
result in reduced DNA binding and transactivation of target genes, as well as loss of TBX5 
interaction (16).  In addition to NKX2.5 and TBX5, GATA4 associates with a variety of 
binding partners thought to create specific transcriptional complexes that confer tissue-
specific gene expression during heart development (Table 2.1) (12, 19).  
 Familial defects in cardiac septation have recently been associated with a third 
cardiac transcription factor, Tbx20 (NM_020496).  As previously described, Tbx20 is a 
member of the T-box family of transcription factors and is one of the earliest markers of 
vertebrate cardiogenesis (1, 10, 14, 22, 27, 33). TBX20 has been shown to be required for 
proper vertebrate heart development, as reduced levels of TBX20 have been shown to disrupt 
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cell specification, proliferation and chamber differentiation (13, 45, 47, 48).  Recently, a 
novel screen of 352 CHD-affected propositi for mutations in the Tbx20 locus revealed one 
missense and one nonsense mutation to be associated with a family history of CHD (24).  
The missense mutation, I152M, which disrupts a highly conserved amino acid of the T-box 
DNA-binding domain, results in decreased Tbx20 function and is clinically manifest by both 
ASDs and VSDs (24).  The nonsense mutation, Q195X, on the other hand, results in a 
truncated TBX20 protein product through the introduction of a stop codon into one exon of 
the region encoding the T-box domain.  Probands identified to carry the Q195X nonsense 
mutation presented with a wider range of CHDs which includes not only ASDs and VSDs, 
but also mitral valve stenosis, DCM, apicolateral hypertrophy, dilated LV and pulmonary 
hypertension (24).  This broad range of defects, taken in the context of the nature of the 
specific mutation is in part representative of TBX20 haploinsufficiency and is consistent with 
the wide expression profile of Tbx20 and the severe phenotypes observed in TBX20 null 
mice (13, 45, 47, 48).  It is interesting, however, that the human clinical presentation 
resulting from the Q195X mutation is much more severe than the phenotype of heterozygous 
mice.  This is similar to mouse models of Nkx2.5 and may suggest an importance of modifier 
genes in TBX20 expression (12). 
 
Holt-Oram Syndrome:  Tbx5 
 Holt-Oram syndrome (HOS, OMIM #142900) is an autosomal dominant condition 
that occurs in approximately one of every 100,000 live births.  HOS generally presents highly 
variable phenotypes including both upper limb and cardiac defects. Though rare, there is 
much to learn from its presentation of CHDs, which range from single or multiple ASDs and 
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VSDs, to more complex malformations such as tetralogy of Fallot and hypoplastic left heart 
syndrome (see glossary; Fig. 2.2) (34).  Mild to severe cardiac arrhythmias are also common 
(4). 
The genomic locus responsible for HOS phenotypes was previously mapped to 
chromosome 12q24.1.  Since then, HOS has been linked to more than 30 mutations 
distributed throughout Tbx5 (U80987), generally thought to result in Tbx5 haploinsufficiency 
(21, 34).  Tbx5, like Tbx1, is a T-box containing transcription factor that is essential for 
proper vertebrate tissue patterning and differentiation (37).  Though familial studies and 
studies in mouse have attempted to correlate the location of the many Tbx5 mutations along 
the locus with the wide variation in severity of limb and cardiac defects, there is currently 
insufficient evidence to support such a hypothesis (34).  Currently, it is thought that loss of 
transactivation, reduced interaction with other cardiac transcription factors such as NKX2.5, 
GATA4, and TBX20, or mis-sorting of mutant forms of TBX5 are main causes for HOS 
pathogenesis (Table 2.1) (11, 17, 19). 
 
Okihiro Syndrome: Sall4 
 Okihiro Syndrome (OMIM #126800) is an autosomal dominant condition consisting 
of Duane anomaly, radial ray defects and deafness (see glossary).  The phenotype may 
include cardiac defects, anal stenosis, pigmentary disturbance, renal abnormalities, or facial 
asymmetries.  The specific cardiac defects are most often ASDs, VSDs, or tetralogy of Fallot 
(Fig. 2.2) (8, 26). 
 Familial studies of individuals affected by Okihiro syndrome have identified 
mutations in the Sall4 gene (NM_020436) and suggest that haploinsufficiency of this gene is 
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responsible for the clinical phenotype (2, 7, 25).  Sall4 (spalt-like 4) is a member of the Sal 
gene family, which encodes a group of four probable zinc-finger transcription factors (28).  
Thus far, a total of 11 different mutations over the entire Sall4 gene have been described in 
relation to Okihiro syndrome (2, 25, 26).  In addition, Borozdin (2004) and colleagues 
demonstrated that Okihiro syndrome can also be caused by deletions of either the entire Sall4 
gene or of single coding exons (7).  Based on work with the closely related Sall1, it is likely 
that these mutations result in truncated proteins, possibly having the dominant effect of an 
upregulated repressor (23).  However, at this point there are no known upstream effectors or 
downstream targets of SALL4.  
 
Char Syndrome: TFAP2B 
Char syndrome (OMIM #169100) is an autosomal dominant trait characterized by 
facial dysmorphism, hand anomalies, and patent ductus arteriosus (see glossary; Fig. 2.2).  
Char syndrome has been mapped to chromosome 6p12-p21 and further analyses point to 
inherited mutations within the TFAP2B (transcription factor AP-2 beta) (NM_003221) locus 
as a genetic cause of Char syndrome (31, 42, 52).  TFAP2B encodes a neural crest-related 
transcription factor belonging to the TFAP family, whose members play an important role in 
retinoic acid-induced differentiation (29).  Char syndrome likely results from abnormal 
neural crest development, as neural crest cells are important for the development of several 
affected tissues (35).  TFAP2B mutations associated with Char syndrome inhibit target gene 
activation through a dominant-negative mechanism or cause abnormal mRNA splicing 
resulting in TFAP2B haploinsufficiency (31, 42).  However, the precise molecular 
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mechanisms underlying the effects of aberrant TFAP2B activity resulting in Char syndrome 
remain to be elucidated. 
 
Dilated Cardiomyopathy with Sensorineural Hearing Loss:  Eya4 
 Cardiomyopathy is the leading cause of heart failure and is most commonly 
associated with a dilated cardiomyopathy (DCM) phenotype, defined by increased diastolic 
and systolic ventricular volumes and contractile dysfunction (41).  Often, DCM is presented 
in conjunction with defects of the inner ear resulting in sensorineural hearing loss (SNHL).  
While not typically characterized as a classical CHD, cardiomyopathy is discussed here as 
the origins of its pathophysiology may also result from mutations in cardiac transcription 
factors. 
Several studies have demonstrated that approximately 25% to 30% of DCM cases 
may be familial (41).  Until recently, the significant mortality and late onset of this disease 
hindered work to identify the genomic location of the responsible disease loci.  Schönberger 
and colleagues have identified a human mutation that causes dilated cardiomyopathy and 
associated heart failure in addition to previously described sensorineural hearing loss (43, 
49).  The identified mutation is a 4846 bp deletion of the human gene Eya4 (Y17114), one of 
four vertebrate orthologs of the Drosophila melanogaster gene eyes absent (eya) (9).  EYA4 
is a transcriptional coactivator that interacts with members of the sine oculis family (Six1-
Six6) and Dach transcription factors to lead to gene activation (Table 2.1) (6, 9, 20).  The 
characterization of the human mutation is supported by work in zebrafish, as attenuated eya4 
levels produce the morphological and hemodynamic features of heart failure.  In addition, 
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Schönberger et al. (2002) demonstrate critical roles for EYA4-SIX regulation of transcription 
in normal heart function (43). 
 
Potential Therapies 
In general, transcription factors have historically been poor targets of drug therapy 
due to their nuclear localization, lack of enzymatic activity, and the difficulty associated with 
reprogramming transcriptional networks (Fig. 2.1).  Presently, the most effective therapy for 
cardiac diseases is heart transplantation.  However, due to the shortage of organs, cost, and 
inaccessibility of treatment for most affected individuals, this remains a limited therapeutic 
option.  Alternative treatment is the administration of drugs that improve myocardial 
contractility, though this treatment is only effective as a short-term therapy, with the 5-year 
survival rate using current agents being less then 60% (32).  More recently, new strategies 
have focused on two main approaches for treatment of transcription factor-associated heart 
disease, cardiac stem cell transplants and chemical modulators of transcriptional activity.  
The ability to isolate and propagate cell populations that can differentiate into 
cardiomyocytes in vivo offers the opportunity to treat a wide range of cardiac diseases.  The 
existence of cardiac precursor or stem cells in adults remains a contentious issue.  However, 
recent reports suggest that cardiac precursor or stem cells are present, albeit, in a very low 
number.  In addition to endogenous cardiac stem cells, other studies have shown that 
multipotential cells, most notably embryonic stem (ES) cells and bone marrow-derived stem 
cells have, under defined conditions, differentiated into cardiomyocytes.  Although these 
studies offer the promise of growing cells for use in repairing damaged cardiac tissue, three 
major hurdles must be overcome before stem cells can be considered as a therapy for cardiac 
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disease.  First, the molecular, biochemical, and cellular properties of these different cell 
populations must be established.  Second, studies must demonstrate that precursor cell 
populations can be maintained and expanded to suitable numbers to be used as a cardiac 
therapy while maintaining their multipotentiality.  Finally, results must show multipotential 
cells, once transplanted to the heart, can give rise to functioning cardiomyocytes while not 
undergoing uncontrolled differentiation leading to cardiac teratomas or fibrosis (38).  
An alternative therapeutic strategy for transcription factor-associated cardiac disease 
is to screen small chemical libraries to identify agents that either exacerbate or ameliorate 
transcription factor activities (Fig. 2.1).  These agents could either act in an intercellular 
signaling cascade that turns on, off, or modifies transcription factor activities, most notably 
agents that act in the calcium or phosphate signaling pathways, or act directly on 
transcription co-factors such as histone acetyltransferases (HATs) or histone deactylases 
(HDACs) (32).  The major obstacle is the availability of an inexpensive, quick screen for 
these molecules.  However, recent observations showing the sequence, expression, and 
function of many cardiac disease-associated transcription factors are evolutionarily 
conserved open the possibility of using fish or frog model systems as bioassays to test for 
agents that modulate these pathways. 
 
SUMMARY AND CONCLUSIONS 
Given the number of transcription factors demonstrated to play essential roles in 
vertebrate cardiogenesis, the current pool of CHD-associated transcription factors is likely 
underrepresented.  It is our speculation that more correlations between mutations in cardiac 
transcription factors and CHD will be made.  To this end, disruptions in the function of at 
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least six cardiac transcription factors have been associated with human CHD.   
Haploinsufficiency of the genes Tbx1, Tbx5, GATA4, and Sall4 have been correlated with 
CHDs such as DiGeorge syndrome, Holt-Oram syndrome, familial ASDs and VSDs and 
Okihiro syndrome while similar disruptions in Nkx2.5, TFAP2B, and Eya4 are associated 
with familial ASDs, Char syndrome and cardiomyopathies.  While the identification of genes 
associated with CHD is an important first step towards the goal of curing cardiovascular 
disease, it has become clear that understanding the genetic pathways and the molecular 
mechanisms of transcription factors will be key to our ability to identify therapeutic agents 
for CHD.  Based on our current understanding of these mechanisms and of heart 
development in general, possible treatment options may eventually grow to include cardiac 
stem cell transplants and chemical agents.  However, these possibilities lie in the future, and 
their development will rely upon studies using a variety of animal models and our growing 
knowledge of CHD.  
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Figure 2.1 General pathways of cardiac transcription factor regulation.  1. Post-
translational modification of cardiac transcription factors (TF) in response to growth factor 
signaling pathways.  2. Nuclear localization of the cardiac TFs.  3. Protein-protein 
interactions of cardiac TF including potential association with the transcriptional repressors, 
histone deacetylases (HDAC).  4. Sequence specificity or affinity of DNA binding.  5. 
Regulation of transcriptional activity including cardiac TF-associated activation or 
repression.  6. Nuclear export and translation of downstream target genes. Each step 
represents a potential target for drug therapies.  BMP – bone morphogenetic protein, FGF – 
fibroblast growth factor, EGF – epidermal growth factor, IGF – insulin-like growth factor, 
TF – transcription factor, HDAC – histone deacetylase 
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Figure 2.2. Congenital heart defects associated with mutations in cardiac transcription 
factors.  Mutations in cardiac transcription factors such as Tbx1, Nkx2.5, Gata4, Tbx5, Sall4, 
and TFAP2B have been associated with multiple human congenital heart defects including 
atrial septal defects (ASD), ventricular septal defects (VSD), tetralogy of Fallot (TOF), 
conduction system defects (CD), hypoplastic left heart (HLH), pulmonary atresia (PA), 
patent ductus arteriosus (PDA), tricuspid atresia (TA), and truncus arteriosus (TRA). 
Schematic shows the relative position of each defect. 
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Human Clinical 
Manifestation 
Associated 
Transcription 
Factor 
Co-factors/ 
Upstream 
Molecules 
Potential Downstream 
Cardiac Genes References 
DiGeorge 
Syndrome Tbx1 
VEGF, FOXc1, 
FOXc2 Fgf8 
 (3, 12, 15, 
18, 19, 50, 
51) 
Familial ASD Nkx2.5 GATA4, TBX5 
Nppa/ANF, Bnp, 
eHand, Mef2C Mlc2V, 
Msx2, N-Myc 
 (5, 12, 17-
19, 30, 44) 
Familial 
ASD/VSD Gata4 
FOG2, GATA6, 
MEF2C, 
NFATc4, 
NKX2.5, SRF, 
TBX5 
Nppa/ANF, a/b-MHC, 
Cardiac a-actin, 
Cardiac TnC,Cardiac 
TnI, Gata6, Nkx2.5 
(12, 16-19, 
36, 40)  
Septal and 
Valvulogenesis 
Defects and 
Cardiomyopathy 
Tbx20 GATA4, GATA5, NKX2.5, TBX5 Nppa/ANF, Tbx2 (11, 45-47) 
Holt-Oram 
Syndrome Tbx5 
GATA4, NKX2.5, 
TBX20 
Nppa/ANF, Cx40, 
Gata4, Hey2, Irx4, 
Mlc2v, Nkx2.5 
 (4, 11, 12, 
17-19, 21, 
34, 37) 
Okihiro Syndrome Sall4 Unknown Unknown 
(2, 7, 8, 19, 
23, 25, 26, 
28) 
Char Syndrome TFAP2B Unknown Unknown (17, 31, 42, 52) 
Dilated 
Cardiomyopathy 
with Sensorineural 
Hearing Loss 
Eya4 SIX, DACH Unknown  (6, 9, 19, 20, 43, 49) 
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Table 2.1.  Human CHDs, associated transcription factors and molecular interactions  
Abbreviations:  VEGF-vascular endothelial growth factor; FOXc1/2-human forkhead-box 
subfamily c1/2; GATA-GATA binding protein; TBX-T-box; FOG2-friend of GATA; 
MEF2C-myocyte enhancer factor 2C isoform; NFATc4-nuclear factor of activated T cells, 
cytoplasmic, calcineurin-dependent-4; NKX2.5-NK2-related homeobox; SRF-serum 
response factor; Fgf8-fibroblast growth factor 8; Nppa/ANF-natriuretic peptide precursor 
a/atrial natriuretic factor; Bnp-brain natriuretic peptide; eHAND-heart- and neural crest 
derivatives-expressed 1; mlc2v-myosin light chain-2 ventricular isoform; Msx2-muscle 
segment homeobox 2; N-Myc-neuroblastoma-myelocytomatosis viral-related oncogene; α/β-
MHC-alpha-, beta- myosin heavy chain; TnC-troponin C; TnI-troponin I; Cx40-connexin 40; 
Hey2-hairy/enhancer of split-related with YRPW motif-2; Irx4-iroquois 4
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GLOSSARY 
 
Monoallelic microdeletion – Loss of a small fragment of one allele of a gene 
Tetralogy of Fallot – A congenital heart defect characterized by a malformation of the ventricular 
septum, enlargement of the right ventricle, misplacement of the aortic origin, and a narrowing of the 
pulmonary artery  
Interruption of the aortic arch type B – A congenital heart defect characterized by an interruption 
between the left carotid artery and the left subclavian artery 
Ventricular Septal Defect – A congenital heart defect characterized by an abnormal opening 
between the cardiac ventricles, usually resulting from failure of the spiral septum to close the 
interventricular foramen and allowing blood to pass directly from the left to the right ventricle 
Pulmonary Atresia – A congenital heart defect characterized by the absence of the normal valve into 
the pulmonary artery 
Persistent Truncus Arteriosus – A congenital cardiovascular defect resulting from the failure of the 
septum between the aorta and pulmonary trunk to develop and characterized by a common arterial 
trunk opening out of both ventricles with the pulmonary arteries branching from the ascending 
common trunk 
Hypoplastic Left Heart Syndrome – A congenital heart defect in which the left side of the heart is 
underdeveloped resulting in insufficient blood flow 
Duane Anomaly – A congenital eye movement disorder characterized by an absence of abduction, 
restricted adduction and retraction of the globe on attempted adduction  
Radial Ray Defects – Congenital malformations of the forelimbs 
Patent Ductus Arteriosus – A cardiovascular defect in which the ductus arteriosus fails to close after 
birth 
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CHAPTER 3 
DEVELOPMENTAL EXPRESSION PATTERNS OF TBX1, TBX2, 
TBX5, AND TBX20 IN XENOPUS TROPICALIS 
 
 
 
PREFACE 
 Chapter 3 focuses on the evolutionary conservation of T-box gene orthologs in X. 
tropicalis, and emphasizes its utility as a model organism for studies of gene function.  While 
T-box genes such as Tbx5 and Tbx20 have been previously characterized in X. laevis, their 
expression pattern in the closely related diploid species X. tropicalis remained unexplored.  
Through these studies, the importance and utility of X. tropicalis in genetic studies of gene 
regulation is emphasized. 
 This work was previously produced and published in collaboration with Dr. 
Christopher Showell and Kathleen S. Christine.  I was directly involved with the work 
pertaining to Tbx20 sequence conservation and expression.  Additionally, I participated in the 
writing and editing of the manuscript for publication.   
 
Showell, C., K.S. Christine, E.M. Mandel, and F.L. Conlon.  2006. Developmental 
expression patterns of Tbx1, Tbx2, Tbx5, and Tbx20 in Xenopus tropicalis.  
Developmental Dynamics 235(6):1623-1630. 
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SUMMARY 
T-box genes have diverse functions during embryogenesis and are implicated in 
several human congenital disorders. Here we report the identification, sequence 
analysis and developmental expression patterns of four members of the T-box gene 
family in the diploid frog Xenopus tropicalis. These four genes – Tbx1, Tbx2, Tbx5 and 
Tbx20 – have been shown to influence cardiac development in a variety of organisms, in 
addition to their individual roles in regulating other aspects of embryonic development. 
Our results highlight the high degree of evolutionary conservation between orthologues 
of these genes in X.tropicalis and other vertebrates, both at the molecular level and in 
their developmental expression patterns, and also identify novel features of their 
expression. Thus, X.tropicalis represents a potentially valuable vertebrate model in 
which to further investigate the functions of these genes through genetic approaches.  
 
INTRODUCTION 
DNA-binding transcription factors encoded by several members of the T-box gene 
family have been shown to have both cell-autonomous and non-cell autonomous roles in 
controlling the development of the heart during embryogenesis (30, 39). These roles appear 
to be conserved during evolution and, in some cases, their importance is highlighted by the 
association between mutations in these factors and the incidence of human congenital heart 
defects (22, 27, 32). In addition, the same genes have been shown to be required for the 
proper development of other tissues and organs, such as the eye (Tbx5) (17) and ear (Tbx1) 
(20, 24, 28, 31, 41), while other T-box genes have key roles in regulating early embryonic 
patterning (35). 
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Xenopus is a valuable model organism in which to investigate the molecular and 
genetic regulation of organogenesis in general and heart development in particular, and 
reverse genetic approaches have recently been developed to isolate mutant alleles in specific 
genes of interest in the diploid frog Xenopus (Silurana) tropicalis.  In comparison with the 
zebrafish (Danio rerio), Xenopus cardiac morphology is more similar to that of humans, 
including septation of the atrium into left and right chambers (12, 23). Also, the accessibility 
of the embryo throughout development and the high fecundity of the frog are significant 
advantages over the mouse, both in embryological analysis and in genetic screening. 
The genes analyzed here – Tbx1, Tbx2, Tbx5 and Tbx20 – are all known to play 
important roles in regulating normal cardiac development. TBX1 lies within a critical region 
of human chromosome 22 (22q11.2) that is deleted in patients with DiGeorge syndrome, and 
loss of Tbx1 function in the mouse mimics the severe morphological defects of the outflow 
tract of the heart that are seen in DiGeorge patients (14, 21). Similarly, mutations in the 
human TBX5 gene are associated with Holt-Oram syndrome, affecting atrioventricular 
septation, the cardiac conduction system and the development of the upper limbs (4, 19).  
Tbx5 has been shown to act in concert with Tbx20 at the molecular level to control cardiac 
morphogenesis (6). Conversely, Tbx5 and Tbx2 appear to function within distinct domains of 
the developing heart, contributing to the patterning of the early heart tube and its subsequent 
morphological regionalization. A number of recent studies have also demonstrated a 
requirement for Tbx20 function for proper regulation of Tbx2 expression within the 
developing heart (7, 36, 38). As a preliminary step in investigating the molecular basis of 
their developmental roles through genetic analysis in the emerging model organism Xenopus 
tropicalis, we have identified cDNA clones containing full-length coding sequences 
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corresponding to these four T-box genes, determined the structure of their genomic loci in 
silico, and characterized their spatial expression patterns over a wide range of stages during 
embryogenesis. Our results demonstrate the high degree of sequence conservation of T-box 
gene orthologues in Xenopus tropicalis and highlight both conserved and previously 
undescribed aspects of their embryonic expression. 
 
RESULTS AND DISCUSSION 
Sequence analysis of Xenopus tropicalis T-box gene orthologues 
cDNA clones corresponding to Tbx1, Tbx2 and Tbx20 were identified by BLAST 
searches within a database of Xenopus tropicalis expressed sequence tags and a clone 
containing the translation initiation codon was obtained and sequenced for each gene. A 
cDNA encoding the X.tropicalis orthologue of Tbx5 was cloned by RT-PCR and sequenced. 
These cDNA sequences were used to search the X.tropicalis draft genome sequence (DoE 
Joint Genome Institute) for genomic scaffolds containing the corresponding loci. The cDNA 
sequences were then mapped onto the genomic locus sequences and the exon/intron 
boundaries were identified based on consensus sequences for eukaryotic splice donor and 
acceptor sites (25). 
All four Xenopus tropicalis cDNA clones exhibit a very high degree of sequence 
identity when compared with their Xenopus laevis orthologues, particularly within their 
coding regions. The 1389nt open reading frame within the 3065bp Tbx1 cDNA is 94% 
identical to that of Xenopus laevis Tbx1 (Genbank Acc. # AF526274) (89% identity in 
untranslated regions). The degrees of identity and similarity between the conceptually 
translated Xenopus tropicalis Tbx1 coding sequence and several vertebrate orthologues are 
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shown in Table 3.1. The results of our analysis of the genomic Tbx1 locus are shown in 
Figure 3.1a. 
The 3510bp Tbx2 cDNA identified here contains a 2055nt open reading frame with 
94% identity to Xenopus laevis Tbx2 (Genbank Acc. # AB032941) (86% identity in 
untranslated regions). Table 3.1 shows the degrees of identity and similarity between 
conceptually translated Xenopus tropicalis Tbx2 and vertebrate orthologues. Mapping of the 
Tbx2 cDNA sequence to the available genome sequence identified a 14,129bp region 
containing the complete cDNA sequence divided amongst seven exons (Fig. 3.1b). 
Xenopus tropicalis Tbx5 is encoded by a 1557nt open reading frame. Alignment of 
this sequence with the Xenopus laevis Tbx5 cDNA (Genbank Acc. # AF133036) identified 
93% nucleotide sequence identity between the coding regions of the two orthologues. The 
Xenopus tropicalis Tbx5 cDNA encodes a product exhibiting a high degree of evolutionary 
conservation amongst vertebrate species (Table 3.1). Results obtained from in silico analysis 
of the Tbx5 genomic locus are shown in Figure 2.1c. 
The Tbx20 cDNA clone obtained consists of 2117bp, containing a 1320nt open 
reading frame with 93% sequence identity to that of Xenopus laevis Tbx20 (Genbank Acc. # 
AY154394) (75% identity in untranslated regions). Table 3.1 shows the degree of sequence 
identity and similarity between conceptually translated Xenopus tropicalis Tbx20 and its 
orthologues in other vertebrates. The Tbx20 sequence was found to be divided amongst eight 
exons within a 19,354bp region of a single genomic scaffold (Fig. 3.1d). 
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Analysis of Tbx1 expression during embryogenesis 
Tbx1 function is required for normal heart development in vertebrates. It is thought to 
act indirectly, influencing the differentiation of migrating cardiac neural crest cells by 
regulating the expression of one or more intercellular signals emanating from Tbx1-
expressing cells in the pharyngeal endoderm and the mesenchymal core of the pharyngeal 
arches (16). The cardiac neural crest cells contribute to the formation of the outflow tract of 
the heart and the development of this region is severely affected in DiGeorge patients and in 
mouse models of the syndrome. Initial analysis of the phenotype of a hypomorphic Tbx1neo 
allele in the mouse suggests that the observed alignment and septation defects of the outflow 
tract are independent, thus underscoring the value of analyzing more subtle alleles in addition 
to single gene knockouts and larger deletions in vertebrate models (42). To determine the 
spatial patterns of Tbx1 mRNA expression during the course of X.tropicalis embryogenesis, 
whole mount in situ hybridization was performed. At the earliest stage analyzed, stage 10.5 
(early gastrula), no expression of Tbx1 was detected. In early neurulae (stage 13), regionally 
restricted expression was clearly detected in a broad anterior domain surrounding the anterior 
end of the medio-dorsal groove of the neural plate (Fig. 3.2a). Within this broad ectodermal 
domain, two bilateral patches of strong Tbx1 expression were detected flanking the medio-
dorsal groove (Fig. 3.2a,c). These patches marked the posterior boundary of the Tbx1 
expression domain. In late neurulae (stage 19), strong expression was detected in the anterior 
ectoderm (Fig. 3.2d-f). This expression domain appeared to largely exclude the central 
nervous system, commonly defined by the expression of pan-neural markers such as the 
neural cell adhesion molecule (N-CAM) (8). Expression was not detected in the developing 
eye anlagen and cement gland, and was only weakly detected in the region of the neural tube 
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posterior to the eye anlagen. Instead, expression of Tbx1 was found to immediately abut these 
regions of the ectoderm. As at stage 13, two distinct bilateral regions of strong staining were 
observed within the Tbx1 expression domain at stage 19, extending as approximately 
dorsoventral stripes in the ectoderm on either side of the anterior CNS. It is unclear whether 
this Tbx1 expression domain corresponds to the location of the proposed primordium of the 
ectodermal (neurogenic) placodes (33, 34). At early tailbud stage (stage 25), Tbx1 was found 
to be expressed in three distinct areas within the pharyngeal region and in the ventral region 
of each otic vesicle (Fig. 3.2g,h). At stage 33, expression within the otic vesicles extended 
further laterally (Fig. 3.2n). However, in subsequent stages (stages 40, 47) expression 
remained restricted to the ventral and lateral regions of the vesicles. This differs from the 
pattern reported for X.laevis, in which Tbx1 appeared to be expressed throughout the vesicles 
(3). 
Expression of Tbx1 orthologues in the pharyngeal region is broadly conserved 
amongst vertebrate species. Between stages 25 and 33, the elaboration of the expression 
pattern of Tbx1 in this region of the X.tropicalis embryo reflects the morphogenesis of the 
pharyngeal arches. In this region, the cells expressing Tbx1 lay beneath the overlying 
epidermis. At stages 25 and 26, expression was detected in the mandibular and hyoid arches 
(Fig. 3.2g,h,i) and in a third domain corresponding to the future branchial arches, posterior to 
the hyoid arch. At stage 27, at which the first branchial arch becomes fully formed, Tbx1 
expression was detected in four distinct pharyngeal domains – the mandibular, hyoid and first 
branchial arches and a more posterior branchial region (Fig. 3.2j,k). By stage 33, expression 
was also detected in the second branchial arch (Fig. 3.2n). At this stage, Tbx1 appears to 
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mark distinct dorsal and ventral regions within the hyoid, first branchial, second branchial 
and forming third branchial arches.    
 
Analysis of Tbx2 expression during embryogenesis 
In situ hybridization showed that, as in X.laevis (10), Tbx2 is expressed ventrally in 
X.tropicalis early gastrulae (stage 10.5) (Fig. 3.3a,b). However, in contrast to the reported 
expression in X.laevis, Tbx2 is expressed most strongly in the outer layer of ectodermal cells 
in X.tropicalis (Fig. 3.3c). In dissected wholemount embryos and in cryosectioned embryos 
(Fig. 3.3c), very faint staining was observed in the underlying ventral mesoderm. At the late 
gastrula stage (stage 12), expression appeared to be consistently upregulated in a small group 
of cells clustered around the ventral edge of the closing blastopore (Fig. 3.3d). At the early 
neurula stage (stage 13), four regions of ectodermal expression were clearly detected. Strong 
staining was observed in the developing cement gland (Fig. 3.3e) and in a U-shaped domain 
around the proctodeum at the posterior of the embryo (Fig. 3.3g). Two bilateral patches of 
expression were seen in the head, at the edge of the neural plate, in the region of the future 
neurogenic placodes caudal to the eye anlagen (Fig. 3.3f,g). It is unclear whether this domain 
includes both the profundal-trigeminal placodal area and the dorsolateral placodes. In 
Xenopus, the dorsolateral placodes give rise to the lateral line placodes and the otic placodes 
at later stages (34). Finally, a diffuse pattern of Tbx2-positive cells was seen in the ventral 
epidermis (Fig. 3.3h, j-l). At stage 19 (late neurula), expression persists in the cement gland, 
the ventral epidermis, the proctodeal region, the lens placodes, and in a broad placodal area 
caudal to the eye anlagen (Fig. 3.3h-l). In addition, expression was detected in the dorsal root 
ganglia of the future spinal cord (Fig. 3.3i). At stage 21/22, Tbx2 expression was seen in a 
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wishbone-shaped group of cells situated dorsal and caudal to each developing optic vesicle 
(Fig. 3.3m), corresponding to the cranial (profundal and trigeminal) ganglia. Expression was 
found to persist in these cells through tailbud and into early tadpole stages (Fig. 3.3n-r). From 
stage 21/22 onwards, the bilateral expression of Tbx2 in the ectodermal placodes became 
restricted primarily to the otic placode and the developing otic vesicles. Unlike Tbx1, Tbx2 
was found to be expressed throughout the otic vesicles, and this expression was detected at 
all subsequent stages analyzed (stages 24 to 40). At stage 24, additional staining was 
observed in the precursors of the hypaxial muscles and the pronephric duct in the trunk, in 
the developing branchial arches, and in the primordium of the heart (Fig. 3.3o,p). A small 
group of cells within the telencephalon is also stained at this stage (Fig. 3.3o-r).  In stage 29 
embryos, expression was clearly detected in the frontonasal process (Fig. 3.3q). Tbx2 
continues to be expressed in the same regions of the embryo at stage 33, although its 
expression becomes clearly regionalized in the looping heart. A higher level of expression 
was clearly detected in the ventricle compared with the atrium, as reported in other 
organisms (Fig. 3.3r). 
 
Analysis of Tbx5 expression during embryogenesis 
The expression pattern of Tbx5 was analyzed at developmental stages from mid-
gastrula (stage 11) to early tadpole (stage 40). No expression was detected at stage 11. In late 
neurulae (stage 19), a gradient of Tbx5 expression was present within the eye anlagen, with 
higher levels dorsally (Fig. 3.4a,b). At this stage, two small patches of cells on either side of 
the embryo were also stained, corresponding to regions within the migrating bilateral heart 
primordia. At early tailbud stage (stage 25), this pattern of expression was maintained in a 
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dorsal region of each developing eye (Fig. 3.4c) and in the heart primordia, located ventrally 
(Fig. 3.4c,d). In stage 26 embryos, the Tbx5-expressing cells of the heart primordia were seen 
to converge at the ventral midline (Fig. 3.4f), while expression was also detected in two 
bilateral groups of cells continuous with and extending dorsally from the heart primordia. 
These cells likely correspond to the progenitors of the right and left branches of the sinus 
venosus and common cardinal veins (11, 26). In other organisms, Tbx5 has been shown to 
play an important role in eye development, particularly in guiding the projection of neurons 
between the retina and tectum (17). In X.tropicalis, expression in the dorsal region of the eye 
was found to be maintained until early tadpole stages (stage 40), although its expression 
becomes greatly restricted between stages 33 and 40 (Fig. 3.4h,i). At stage 31/32, strong 
expression was detected in the posterior region of the heart tube in cleared embryos (Fig. 
3.4g). Following looping of the heart, a higher level of expression was detected in the 
ventricle (situated ventrally and offset to the left side of the embryo) than in the atrium (Fig. 
3.4j). The regional differences in the expression of Tbx5 within the hearts of X.tropicalis 
tadpoles were seen consistently in both wholemount and sectioned embryos. Transverse 
sections through the heart at stages following heart looping showed expression of Tbx5 in the 
ventricular myocardium, while staining was not detected in the atrial region of the heart (Fig. 
3.6b). 
 
Analysis of Tbx20 expression during embryogenesis 
The expression pattern of X.tropicalis Tbx20 was analyzed in embryos between stages 
13 (neural plate stage) and 40 (early tadpole). Although expressed weakly in the developing 
cement gland as early as stage 13 in X.laevis (5), we did not detect expression at this stage in 
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X.tropicalis. At late neurula stage (stage 20), Tbx20 was strongly expressed in the developing 
cement gland and in the bilateral heart primordia (Fig. 3.5a-c). Expression in the cement 
gland was found to decrease from stage 25 onwards, while expression continued to be 
strongly detected in the developing heart.  In the heart-forming region at stage 25, a single 
domain of expression was detected, corresponding to the heart field formed by fusion of the 
bilateral heart primordial (Fig. 3.5e). This fusion of the Tbx20-expressing domains appears to 
occur earlier in X.tropicalis than in X.laevis. Notably, this pattern of expression differs 
considerably from that of Tbx5, in which fusion of the bilateral pre-cardiac expression 
domains begins at around stage 26 (see above). In addition to this cardiac expression, two 
small domains of expression were observed in the hindbrain (rhombencephalon) at this stage, 
corresponding to the second and fourth rhombomeres. At stage 29/30, expression persisted in 
these regions and was also weakly detected in a more posterior region of the hindbrain (Fig. 
3.5f). The hindbrain expression of Tbx20 was found to be upregulated in embryos at 
subsequent stages and, as in more anterior regions, was detected in distinct paired 
subdomains (Fig. 3.5g,j,k,m,n). At stage 33, when heart looping is initiated, Tbx20 was found 
to be broadly expressed in the heart tube, with strong staining detected in the ventricle, 
atrium and both branches of the sinus venosus (inflow tract) (Fig. 3.5g,i). Thus, the 
expression domain of Tbx20 in the developing chambers of the heart tube only partially 
overlaps that of Tbx5. This is consistent with the patterns of Tbx20 expression reported in 
other vertebrates (1, 5, 18, 29, 43). During heart looping (stage 36), Tbx20 was expressed at a 
higher level in the atrium than in the ventricle (Fig. 3.5l). This regional difference in the 
expression level of Tbx20 was maintained in early tadpole stage embryos (stage 40) and was 
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clearly seen both in whole embryos and in transverse sections through the heart (Fig. 3.5o., 
3.6c). 
 
MATERIALS AND METHODS 
Identification and isolation of cDNA clones  
cDNA clones TNeu106g11, TGas050k23 and TTpA031n09, encoding X.tropicalis 
orthologues of Tbx1, Tbx2 and Tbx20 respectively, were identified by searching a database of 
X.tropicalis expressed sequence-tagged clones derived from oligo-dT primed cDNA libraries 
specific to several developmental stages (www.sanger.ac.uk; (9)). Specifically, nucleotide 
sequences from the 5’ ends of the coding regions of the corresponding X.laevis orthologues 
(Tbx1 Genbank Acc. # AF526274; Tbx2 Genbank Acc. # AB023815; Tbx20 Genbank Acc. # 
AY154394) were used to BLAST search (2) for X.tropicalis clones containing the predicted 
translation start codon and which were therefore likely to contain full-length cDNAs. The 
clones were obtained (MRC Geneservice) and the cDNA inserts were sequenced. A cDNA 
encoding Tbx5 was cloned by low-stringency RT-PCR, using total RNA template from stage 
13-20 X.tropicalis embryos. Primers were designed based on sequences flanking the X.laevis 
Tbx5 coding sequence (forward: 5’-GAAGATCTATGGCGGACACAGAGGAGGCT-3’; 
reverse: 5’-GAGAGATCTACGCTGTTTTCATTCCAGTCTGG-3’). The resulting product 
was cloned into pcDNA3.1 (Invitrogen Corp.). All cDNA sequences are deposited in 
Genbank (Tbx1 accession # DQ124205; Tbx2 accession # DQ124206; Tbx5 accession # 
DQ124207; Tbx20 accession # DQ124208). 
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In silico analysis 
To identify genomic sequence scaffolds corresponding to Tbx1, Tbx2, Tbx5 and 
Tbx20, the corresponding cDNA sequences were used to search the X.tropicalis draft genome 
sequence (versions 2.0 and 3.0) using the BLAST algorithm (2) (DoE Joint Genome 
Institute). Pairwise sequence alignments and analyses of sequence conservation of 
conceptually translated proteins were performed using GeneDoc 
(www.psc.edu/biomed/genedoc). 
 
Embryo collection and in situ hybridization 
X.tropicalis embryos were collected following natural single-pair mating between 
animals from a partially inbred (F6) line (NASCO). Males and females were pre-primed with 
ten units of human chorionic gonadotropin (hCG; Sigma) twenty hours before being primed 
with an additional two hundred units. One hour after priming, males and females were paired 
and allowed to mate for approximately five hours in shallow water at 25ºC. Embryos and 
unfertilized eggs from successful matings were collected, treated with 2% cysteine 
hydrochloride to remove their jelly coat, and sorted. Embryos were cultured at 25ºC in 
sterilized water from our aquatic system and staged according to criteria set out in the 
Normal Table of Xenopus laevis (26). 
A 908bp KpnI-XhoI fragment of the Tbx1 EST clone was subcloned into pBluescript-
KS and this construct was linearized with Acc657 to generate a template for in situ 
hybridization probe synthesis. Template for Tbx2 probe synthesis was produced by 
linearizing the full-length cDNA clone described above using HindIII. The Tbx5 cDNA was 
cut from pcDNA3.1-Tbx5 by NotI-SpeI digest and sub-cloned into pBluescript-KS to generate 
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a probe template construct that was subsequently linearized with NotI. To generate a template 
for Tbx20 probe synthesis, a 565bp SalI-NotI fragment from the Tbx20 EST clone was sub-
cloned into pBluescript-KS and the construct linearized using SalI. In situ hybridizations 
were performed according to a standard protocol (37) with the following exceptions: Fixed 
embryos were devitellinized by enzymatic treatment with collagenase A (Roche Applied 
Science), proteinase K and hyaluronidase (Sigma) (13). No further proteinase K treatment 
was performed. Embryos were pre-hybridized overnight (approx. 15 hours) and the RNase 
treatment step prior to antibody incubation was omitted (15). After staining with BM Purple 
alkaline phosphatase substrate (Roche Diagnostics), embryos were re-fixed in 1X MEM salts 
containing 10% formamide and then dehydrated in methanol.  
Where necessary, embryos were cleared in 2:1 benzyl benzoate:benzyl alcohol 
(Sigma). Embryos were photographed on a Leica M-series stereomicroscope (Leica 
Microsystems Ltd.) using the Spot Advanced image capture system (Diagnostic Instruments 
Inc.) and edited using Photoshop 7.0 (Adobe Systems Inc.). 
 
Cryosectioning 
For cryosectioning, embryos were embedded in gelatin using a method modified from 
Stern and Holland (40). Following in situ hybridization, embryos were fixed in 4% 
paraformaldehyde in PBS and incubated overnight at 4ºC in 30% sucrose/PBS (w/v). The 
embryos were then pre-warmed to 38ºC before being transferred to 15% sucrose/PBS 
containing 7.5% gelatin (~300 Bloom; SIGMA) at 38ºC. Embryos were incubated in gelatin 
for a minimum of thirty minutes before being transferred to specimen molds (Tissue-Tek; 
Sakura Finetek U.S.A., Inc.). Embedded embryos were stored at 4ºC prior to cryosectioning. 
 53 
Sections were taken at a thickness of 20µm. Gelatin was rinsed from the sections using PBS 
at 38ºC before mounting in aqueous mounting medium (Faramount; DakoCytomation). 
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Table 3.1. Sequence conservation of T-domain protein orthologues in vertebrates.  
X.tropicalis Tbx1, Tbx2, Tbx5 and Tbx20 were analyzed by pairwise alignment with their 
orthologues in X.laevis (African clawed frog), Danio rerio (zebrafish), Gallus gallus 
(chicken), Mus musculus (mouse) and Homo sapiens (human). Overall sequence identity and 
similarity (in parentheses) between amino acid sequences are shown as percentages. Where 
putative full-length sequences were not available, these comparisons were omitted (N/A). 
 Xenopus 
laevis 
Danio 
rerio 
Gallus 
gallus 
Mus 
musculus 
Homo 
sapiens 
Tbx1 97% (98%) 80% (87%) N/A 71% (79%) 69% (77%) 
Tbx2 96% (97%) 77% (84%) N/A 70% (77%) 70% (77%) 
Tbx5 95% (96%) 64% (73%) 81% (87%) 78% (85%) 78% (85%) 
Tbx20 97% (98%) 85% (92%) 90% (95%) 90% (95%) N/A 
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Figure 3.1. Genomic locus structure of Tbx1, Tbx2, Tbx5 and Tbx20 in X.tropicalis.  
Tbx1, Tbx2, Tbx5 and Tbx20 cDNAs and their corresponding genomic loci are shown in 
diagrammatic form (not to scale). Coding regions of each cDNA are shown (boxes) together 
with their nucleotide positions and the position of the T-box (defined by alignment of the 
encoded proteins with the T-domain of Xbra) is also indicated. The exons corresponding to 
the cDNA sequences are shown together with their sizes (in base pairs) plus those of the 
intervening introns. Note that as the size of the first exon of each gene is predicted based on 
the available cDNA sequence, the sizes of these exons may be underestimated here. 
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Figure 3.2. Expression pattern of Tbx1 in X.tropicalis.  The results of in situ hybridizations 
for Tbx1 expression from early neurula to late tailbud stages are shown (embryos uncleared). 
Except for the anterior views shown in a) and d), all embryos are oriented with anterior to the 
left. Stage 13 is shown in anterior (a), lateral (b) and dorsal (c) views. Bilateral patches of 
stronger expression are indicated in a) by arrowheads. Stage 19 is shown in anterior (d), 
lateral (e) and dorsal (f) views. Bilateral stripes of stronger expression are indicated in f) by 
an asterisk. Tbx1 expression through tailbud stages is shown as follows: Stage 25 lateral (g) 
and ventral (h), stage 26 lateral (i), stage 27 lateral (j) and ventral (k), stage 28 lateral (l) and 
ventral (m), stage 33 lateral (n). ba1 first branchial arch, ba2 second branchial arch, cg 
cement gland, ea eye anlagen, ha hyoid arch, ma mandibular arch, ov otic vesicle.  
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Figure 3.3. Expression pattern of Tbx2 in X.tropicalis.  In-situ hybridization results are 
shown for Tbx2 (embryos uncleared). Expression at early gastrula (stage 10.5) is shown in 
lateral (a) and vegetal (b) views of wholemount embryos, and in transverse section (c; ventral 
to the right). In both a) and b), the embryo is oriented with dorsal to the left and the dorsal 
blastopore lip is indicated by an arrowhead in a). A vegetal view of a late gastrula (st12) is 
shown in d), ventral side uppermost. Expression at early neurula (stage 13) (e-g) late neurula 
(stage 19) (h,l) and tailbud stages 21/22 (m), 25 (n), 26 (o,p), 29 (q) and 33 (r) are also 
shown. Expression in the forebrain (telencephalon) at tailbud stages is indicated by an 
asterisk (o-r). Except for anterior (d,j) and posterior (l) views, all embryos are oriented with 
anterior to the left. cg cement gland, crg cranial ganglia, drg dorsal root ganglia, fn 
frontonasal process, hm hypaxial muscle, ht heart tube, lp lens placode, ov otic vesicle, pd 
pronephric duct, pr proctodeum.  
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Figure 3.4. Expression pattern of Tbx5 in X.tropicalis.  The expression pattern of Tbx5 
detected by in situ hybridization between late neurula and early tadpole stages is shown 
(uncleared except for g). Stages are as follows: Stage 19 (a,b), stage 25 (c,d), stage 26 (e,f), 
stage 31/32 (g) (cleared), stage 33 (h), and stage 40 (i,j). Except for the anterior view in b) 
and the ventral view in j), embryos are oriented with anterior to the left. Anterior is to the top 
in j). ea eye anlagen, hp heart primordium, v ventricle. 
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Figure 3.5. Expression pattern of Tbx20 in X.tropicalis.  The expression pattern of Tbx20 
detected by in situ hybridization between late neurula and early tadpole stages is shown 
(embryos uncleared). Stages are as follows: Stage 20 (a-c), stage 25 (d, e), stage 29/30 (f), 
stage 33 (g-i), stage 36 (j-l), and stage 40 (m-o). Except for the anterior view in a), embryos 
are oriented with anterior to the left. a atrium, cg cement gland, h heart, hb hindbrain, hp 
heart primordium, ht heart tube, sv sinus venosus, v ventricle. 
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Figure 3.6. Cardiac expression of Tbx2, Tbx5 and Tbx20.  The in situ hybridization 
patterns of Tbx2, Tbx5 and Tbx20 in the forming cardiac chambers were examined in 
transverse sections through the tadpole heart after looping. a) Tbx2 expression was seen in 
the myocardium of both the atrial (am) and ventricular (vm) regions of the looped heart at 
stage 36. b) Expression of Tbx5 was restricted primarily to the developing ventricular 
myocardium at stage 38. c) In contrast to Tbx5, high levels of Tbx20 expression were seen in 
the atrial region but not in the ventricle (stage 40). Magnification: 100X.  
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CHAPTER 4 
 
EXPRESSION VIA A NOVEL REGULATORY 
ELEMENT OF THE CARDIAC GENE Tbx20 IS REGULATED 
BY BMP SIGNALING 
 
 
 
PREFACE 
 Chapter 4 describes the growth factor controlled regulation of Tbx20 expression in the 
Xenopus heart.  With Nkx2.5 and Tbx5, Tbx20 is one of the earliest markers expressed in the 
developing heart and has been shown to be essential for proper cardiac development.  
However, until now, the signaling pathways involved in the tissue-specific expression of 
Tbx20 remained unknown.  Here, we demonstrate that a conserved, 334bp regulatory element 
located directly upstream of Tbx20 is both necessary and sufficient to drive its expression in 
the heart.  Additionally, we show that this element is regulated by BMP signaling through 
direct binding of SMAD1 to multiple SMAD binding sites.  Thus, this work represents the 
first characterization of Tbx20 regulation in the heart, and further expands our understanding 
of the transcriptional regulatory networks that govern cardiogenesis. 
 This work represents a collaborative effort with Thomas E. Callis, Dr. Da-Zhi Wang, 
Natalie Thomas and Dr. Deborah Yelon and was recently submitted for publication to the 
journal Circulation Research. For this project, I performed the BAC library screen, 
immunohistochemistry, reporter construct cloning, Xenopus transgenesis, DNA binding 
(Pherastar) assays and completed the writing of the manuscript. 
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Mandel, E.M., T.E. Callis, N. Thomas, D. Yelon, D.Z. Wang and F.L. Conlon. 2007. 
Expression via a novel regulatory element of the cardiac gene Tbx20 is regulated by 
BMP signaling. Circ. Res. In Review. 
 
SUMMARY 
The T-box gene, Tbx20 has been demonstrated to be mutated in human 
congenital heart disease and has been shown to be required for early heart development 
in a wide array of model systems including zebrafish, Xenopus and mouse. Despite the 
evolutionarily conserved requirement for TBX20 in the control of a range of cardiac 
cellular processes, the signal transduction pathways that lie upstream of Tbx20 remain 
completely unknown. Here, we describe the first example of specific growth factor-
controlled regulation of Tbx20 gene expression in the developing heart. We have 
identified and characterized a conserved 334bp regulatory element located upstream of 
the Tbx20 locus that is both necessary and sufficient to drive cardiac specific expression 
of Tbx20 in Xenopus and zebrafish. We further demonstrate that activation of Tbx20 is 
dependent on a novel regulatory element that contains seven distinct canonical and 
non-canonical SMAD high affinity binding sites. This therefore represents evidence for 
a direct role of the BMP/SMAD signaling pathway in the regulation of cardiac Tbx20 
expression. 
 
INTRODUCTION 
Members of the T-box protein family have been demonstrated to play critical roles in 
heart development and disease. For example, patients with Holt-Oram Syndrome (HOS) 
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syndrome frequently lack Tbx5 (15, 34). Recently, clinical studies have also implicated the 
T-box containing protein TBX20 in human congenital heart disease (21). Specifically, 
familial mis-sense or non-sense mutations within the DNA binding domain or T-box of 
Tbx20 are associated with a wide range of cardiac defects in humans including septal defects, 
abnormal valve formation and altered cardiomyocyte growth (21).  
Studies of Tbx20 orthologues in a wide range of model systems including mouse 
(Tbx12/20) (7, 22), zebrafish (Tbx20/HrT) (1, 14), chick (19), and Xenopus (3) have shown 
that along with Tbx5 and Nkx2.5, Tbx20 is one of the earliest genes expressed in the 
vertebrate cardiac lineage. Tbx20 continues to be expressed in the heart until adulthood and 
moreover, appears to be expressed in all regions of the developing heart including the atria, 
ventricles, inflow and outflow tracts, and the septum transversum.  Consistent with these 
findings, as well as clinical studies of human congenital heart disease, Tbx20 orthologues 
have been shown to be required for proper cardiogenesis in zebrafish (49), Xenopus (4), and 
mouse (5, 44, 47, 50).  Thus, the sequence, expression and function of Tbx20 appear to be 
evolutionarily conserved.  
Despite the critical role for Tbx20 in heart development and disease, very little is 
known about the signal transduction pathways that function upstream to regulate Tbx20 
expression in cardiac tissue.  However, studies on the regulation of T-box gene during 
gastrulation have suggested that many of the signal transduction pathways that are necessary 
for early cardiac induction, such as transforming growth factor-β (TGFβ) and Wnt, may also 
be function to activate or maintain T-box expression. For example, Brachyury, the founding 
member of the T-box gene family is expressed throughout newly formed mesoderm, with 
Xenopus Brachyury (Xbra) expression induced in tissue explants in an immediate early 
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response to the TGF-β family member activin (45). Subsequent studies have gone on to show 
that TGF-β signaling is required for Xbra expression in vivo (17). Based on these findings, 
the region of the Xbra promoter was cloned and shown to contain elements that confer a 
dose-dependent response to activin (9, 26, 27, 48).  
In addition to activin, members the TGF-β family include nodal, anti-Muellerian 
hormone (AMH) and bone morphogenetic proteins (BMPs), all of which function by binding 
to specific heteromeric serine/threonine kinase receptor complexes located at the cell 
membrane.  This association leads to the phosphorylation of SMAD molecules, the 
cytoplasmic mediators of the signal transduction pathway.  Specifically, TGF-β, nodal and 
activin molecules induce the activation of the receptor-regulated SMADs 2 and 3, while 
alternatively, the AMH and BMP molecules signal through receptor-regulated SMADs 1, 5 
and 8.  Once phosphorylated, these receptor-regulated SMADs associate with the common 
mediator SMAD, SMAD4, which facilitates translocation to the nucleus.  Once in the 
nucleus, they bind target DNA sequences and, in conjunction with transcriptional co-factors, 
regulate the transcription of downstream target genes (reviewed in (23, 33)). 
There is substantial evidence for a role for BMP molecules in early heart 
development.  Initial evidence comes from the observation that mutation of the Drosophila 
BMP ortholog Dpp, or mutation in any component of the Dpp signaling cascade, leads to a 
loss of cardiac progenitor cells and thus, a failure of the fly embryo to develop a dorsal 
vessel, the structure analogous to the vertebrate heart (46).  Consistent with these findings, 
promoter analysis of the gene tinman, a gene expressed in the dorsal vessel and required for 
its formation, has shown that induction of tinman expression requires Dpp, and its effectors 
Mad (SMAD1) and Medea (SMAD4), which directly bind to elements within the tinman 
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enhancer (55).   The role of BMPs in vertebrate cardiac development is also supported by the 
phenotypic analysis of BMP pathway mutations in the mouse.  For example, conditional 
mutations in the BMP receptor ALK3 in cardiomyocytes lead to a thinning of the trabeculae 
and abnormal cushion formation (12).  The function of these molecules is further emphasized 
by the observation that mutations in genes within the BMP pathway are associated with 
human congenital heart disease (20, 56).  However, due to potential redundancy within the 
BMP family, and the early lethality of embryos mutant for a number of BMP signaling 
pathway components, the precise role for any one member of the BMP family in cardiac 
development remains unclear (40). 
To characterize the growth factor pathways that lead to cardiac expression of Tbx20, 
we have begun to define the cardiac regulatory elements within the Tbx20 locus. This work 
has led to the identification of a 334bp regulatory element that is both necessary and 
sufficient for Tbx20 expression in the heart during cardiac chamber formation. We go on to 
demonstrate that this element is sufficient to drive cardiac-specific expression in living 
zebrafish, demonstrating that the signal transduction pathways acting upstream of Tbx20 are 
evolutionarily conserved between fish and frogs.  We further show that this minimal cardiac 
element is regulated by the BMP pathway and its mediators SMAD1 and SMAD4, but not by 
the TGF-β/Activin/Nodal mediator SMAD3, and that Tbx20 is co-expressed with nuclear 
localized SMAD1 during cardiac chamber formation. Finally, we demonstrate that the 
minimal cardiac Tbx20 element contains seven canonical and non-canonical high affinity 
SMAD binding sites that are directly bound by SMAD1 protein and are necessary in a 
combinatorial fashion for proper regulation of Tbx20.  Collectively, these studies support a 
role for BMP molecules such as BMP2/4 during cardiac chamber formation and provide the 
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first insights into the pathways by which cardiac signaling cascades regulate Tbx20 
expression. 
 
MATERIALS AND METHODS 
In Situ Hybridization and Immunohistochemistry 
X. laevis embryos were collected and fixed in 4% parformaldehyde in phosphate buffered 
saline (PBS) for 2hrs. at room temperature and stored at 4oC in PBS for up to one week.  
Embryos were placed in a 30% sucrose/PBS solution at 4oC overnight before being 
embedded and frozen in OCT cryosectioning medium (TissueTek).  In situ hybridization was 
performed on 20µm transverse cryostat sections using a DIG-labeled Tbx20 RNA probe (3).  
The RNA probe was detected using an anti-digoxigenin Fab-AP antibody (Roche, 1:2000) 
following the manufacturer’s protocol. For immunohistochemical analysis, frozen transverse 
sections (14µm) were rinsed with wash buffer (1% Triton X-100, 1% heat-inactivated lamb 
serum in PBS) and incubated overnight at 4oC with one of the following primary antibodies 
diluted in wash buffer:  rabbit anti-GFP (AbCam, 1:5000), mouse anti-tropomyosin 
(Developmental Studies Hybridoma Bank, 1:50), or rabbit anti-Smad 1/5/8 (Cell Signaling, 
1:50).  The sections were then rinsed with wash buffer and incubated for 30mins. at room 
temperature with the corresponding secondary antibody diluted in wash buffer as follows:  
Alexa 488 anti-rabbit (Molecular Probes, 1:500) or Cy3 anti-rabbit (Sigma, 1:100).  Sections 
were then rinsed with wash buffer and incubated for 30mins. at room temperature with DAPI 
(Sigma).  Histological sections were viewed using a Nikon Eclipse E800 microscope. 
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BAC Library Screen, RLM-RACE 
The ISB-1 X. tropicalis bacterial artificial chromosome (BAC) library [Children’s Hospital 
Oakland Research Institute (CHORI)] was screened using a 317bp PCR product amplified 
from the 5’ terminus of the X. laevis Tbx20 coding region, and BAC DNA prepared 
according to protocols described by CHORI.  DNA was digested with a series of restriction 
enzymes, and analyzed using field inversion gel electrophoresis (FIGE) and Southern blot 
analysis with a Tbx20 probe. From this analysis, a 4114bp EcoRI fragment of Tbx20 was 
identified and ligated into the pBSII-KS+ vector (Stratagene). The transcriptional start site of 
X. tropicalis Tbx20 was identified using the First Choice RLM-RACE Kit (Ambion) and 5’ 
RLM-RACE as described by the manufacturer using whole X. tropicalis embryos (N=25) as 
well as brain-enriched and heart-enriched tissues (approximately 250 embryos for both) at 
stage 28. RNA was isolated using Trizol Reagent (Invitrogen).  
 
Tbx20-EGFP Reporter Constructs 
Tbx20-EGFP reporter constructs for transgenesis were generated by introducing a BamHI 
site into Exon 1 of Tbx20 at position +142 in the Tbx20-pBSII-KS+ construct using the 
QuickChange Site-Directed Mutagenesis Kit (Stratagene).  Following BamHI digestion and 
re-ligation, an AflII site was introduced into the pBSII-KS+ backbone of the modified 
construct upstream of the NotI site.  The EGFP reporter contained within the pEGFP-N1 
vector (Clontech) was then isolated by BamHI/AflII digestion and subcloned into the 
modified Tbx20-pBSII-KS+ construct by BamHI/AflII to create the Tbx20(-2464)-EGFP 
reporter vector containing 2601bp of the 5’ end of Tbx20 driving an EGFP reporter 
(GenBank Accession  #1047274). A Tbx20-EGFP deletion series was generated by 
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substituting elements of Tbx20 ranging from 471-2106bp, each containing a 5’ EcoRI linker 
and a 3’ BamHI linker, for the original 2601bp of the Tbx20-EGFP construct. Details and 
primer sequences are available upon request.  
 
Xenopus laevis Embryo Culture and Xenopus Transgenesis 
Wildtype Xenopus laevis embryos were obtained and cultured using standard methods. 
Staging was performed according to Nieuwkoop and Faber (35). The Tbx20 reporter 
constructs described were linearized by KpnI, and transgenesis performed according to 
previously described methods for restriction enzyme-mediated integration (REMI) (24).  
EGFP expression was analyzed in living embryos using a Leica MZFLIII fluorescent 
dissecting microscope.  For each transgene described, greater than 10 EGFP positive 
embryos were examined in each of at least three independent sets of injections. 
 
Zebrafish Injections 
For injection of zebrafish transgenes, reporter constructs flanked by I-SceI meganuclease 
recognition sites were created from the Tbx20-EGFP reporter constructs utilized for X. laevis 
transgenesis (13). Details and primers are available upon request.  Tbx20-EGFP constructs 
were digested with I-SceI, diluted in dH2O and phenol red in 0.2M KCl to concentrations 
between 0.063 ng/nl and 0.24 ng/nl.  Between 0.5 nl and 1.5 nl of each construct was injected 
into the cytoplasm of single cell zebrafish embryos.  Injected embryos were screened at 
48hpf for GFP expression on a Zeiss M2Bio microscope.  Injections with each construct 
were repeated 4-6 times and data from embryos screened for GFP expression were pooled for 
each. 
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Cell Culture and Luciferase Assays 
Tbx20-luciferase reporter constructs were generated by cloning the respective regions from 
the EGFP reporter constructs into pGL3-Basic (Invitrogen).  For transfection, COS7 cells 
were cultured in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin, and 
transfected using Fugene6 (Roche) reagent.  Cells were transfected with 100ng reporter 
plasmid and indicated expression plasmids.  Expression plasmids used for the transcriptional 
assays have been previously described as follows: 
Myocardin (51, 52) 
SRF  (51, 52) 
pGL3-Nkx2.5 (30) 
Mef2c (53) 
Gata4 (36) 
pRK5 N-Flag Smad1 (31) 
Smad4 (11) 
Smad3 (11) 
SM22 (28)  
Additionally, the mouse Tbx5 coding sequence was cloned into the pcDNA3.1-N-myc vector.  
A CMV-lacZ reporter was used as an internal control to normalize for transfection 
efficiencies, and total amount of DNA per well was kept constant by adding the 
corresponding amount of empty expression vector.  Reporter assays were conducted in 
triplicate at least two times in 12-well plates. Fold induction was calculated as induction 
  76 
compared to that of reporter alone, and error bars refer to the standard deviation of fold 
induction. 
 
Protein-DNA Binding Assays 
Protein Expression 
Human Smad1 cDNA was subcloned from the pRK5 N-Flag SMAD1 construct into the 
pGEX-4T expression vector for the production of a glutathione S-transferase (GST) fusion 
protein, and overexpressed in E. coli (BL21) at 30o C(31).  The GST-SMAD1 fusion protein 
was induced with 100µM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 18 o C overnight 
and purified using Glutathione Sepharose 4B (GE Heathcare).  GST-SMAD1 was eluted 
(50mM Tris-HCl, pH 8.0, 10mM reduced glutathione) and dialyzed (50mM Tris-HCl, pH 
8.0, 100mM NaCl) before concentration.   
 
5’-FAM Oligos 
For 2X coverage of the Tbx20(-334) regulatory element, 21 double-stranded, 30 basepair, 5’-
FAM oligos were designed to overlap by 15 bases beginning from base -1 (Figure 4.6A).  
Additionally, XVent and SRF binding site oligos were designed as positive and negative 
controls respectively, based on previously published work (8, 18). Forward (5’-FAM) oligos 
and reverse strand oligos were resuspended (10 mM Tris, pH8, 150 mM NaCl and 1 mM 
EDTA) and annealed to prepare duplex DNA for binding assays. 
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Fluorescence Polarization 
All fluorescence polarization experiments were performed in a PHERAstar microplate reader 
(BMG Labtechnologies, Durham, NC).  Reactions were performed in triplicate in black, flat-
bottom, half-area, 96-well plates at 25oC.  The 50µL reactions contained 250nmol/L 5’-FAM 
oligo and increasing concentrations of GST-SMAD1 (0-7416.67nmol/L) in reaction buffer 
(10mM Tris-HCl, pH 8.0, 100mM NaCl).  Anisotropy was measured by excitation with 
vertically polarized light, using 490nm excitation and 520nm emission filters with the gain 
optimized for maximum signal and normalized to “no protein” controls.  Data analysis was 
performed using SigmaPlot 8.0 software, and dissociation constants (Kd) determined for each 
oligo using the single rectangular I, 3 parameter equation y=yo + ax/(b+x) where b is equal to 
Kd. 
 
RESULTS 
A Tbx20-EGFP transgene recapitulates the endogenous expression of Tbx20 
To determine the regulatory elements required for Tbx20 cardiac expression, we 
isolated a putative Tbx20 promoter region flanking the 5’ end of the Xenopus tropicalis (X. 
tropicalis) Tbx20 gene by screening the C.H.O.R.I. X. tropicalis ISB-1 Bacterial Artificial 
Chromosome (BAC) library using a 5’ Tbx20 specific probe.  Field inversion gel 
electrophoresis (FIGE) and Southern blotting were used to isolate a 4116bp region of the 
Tbx20 locus.  5’ RLM-RACE on whole embryos (stage 28) and embryonic hearts (stage 28) 
identified a transcriptional start site at a position 287bp upstream of the translational start 
site, and therefore contained in our cloned region of Tbx20 (Figure 4.1A). 
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 To determine the ability of this genomic element to direct cardiac expression of 
Tbx20, we inserted an EGFP reporter cassette in-frame with the TBX20 translational start site 
(Figure 4.1A, B).  Based on our observations that Tbx20 is expressed in an identical pattern 
in X. tropicalis and X. laevis embryos in the cement gland, rhombomeres and heart from 
early stages of development (3, 43), we introduced the Tbx20(-2464)-EGFP reporter into X. 
laevis embryos by restriction enzyme-mediated integration (REMI). Consistent with this 
endogenous pattern of X. tropicalis and X. laevis Tbx20 expression at these stages, the Tbx20 
reporter directed expression of EGFP to the developing heart and cement gland, (≥5 rounds 
of injections; n≥20 EGFP-expressing embryos per experiment)(Figure 4.1C-F).  Specifically, 
EGFP expression was first observed in the cement gland at stage 24 and in the heart at stage 
32 (data not shown).  As the cells of the cement gland began to undergo apoptosis, 
expression of EGFP in the cement gland was gradually reduced to the point that it was absent 
by late tadpole stages (stages 47-48). In contrast, EGFP expression in the heart was 
maintained through chamber differentiation and heart looping (>stage 46; Figure 4.1C-F). 
EGFP expression, however, was never observed prior to early tadpole stages (stage 32). We 
also note that we never observe expression of the Tbx20 reporter in other tissue types that 
express Tbx20 including the hindbrain and eye. Thus, similar to the regulation of other 
cardiac genes such as Nkx2.5 and Mef2c, multiple regulatory elements located throughout the 
Tbx20 locus appear to be required for the complete temporal and spatial pattern of Tbx20 
expression.  
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334bp of upstream sequence is sufficient for Tbx20-EGFP expression 
To begin to define the minimal element necessary for Tbx20 cardiac expression in 
late tadpole stage embryos, we constructed a series of truncated reporters (Figure 4.2A).  
Examination of EGFP expression driven by these reporters reveals that 334bp of upstream 
sequence is sufficient to drive cardiac expression of the Tbx20-EGFP (≥3 rounds of 
injections; ≥20 EGFP-expressing embryos per experiment)(Figure 4.2B-J). We note that the 
same region is also sufficient to drive expression from stage 24 in the cement gland (Figure 
4.2B-C, E-F, H-I). 
To examine the precise tissue distribution of EGFP reporter expression, we serial 
sectioned and immunostained transgenic embryos. Each truncated reporter construct, 
(Tbx20(-2464)-EGFP, Tbx20(-1483)-EGFP and Tbx20(-334)-EGFP), recapitulated 
endogenous Tbx20 expression throughout all cardiac tissue (8/8 EGFP-expressing embryos 
per construct)(Figure 4.2K-P).  In addition, these studies reveal an increase in low levels of 
ubiquitous transgene expression throughout embryos carrying the 334bp reporter, suggesting 
the potential loss of negative regulatory elements located between -1483 and -334bp.  
Collectively, these data show that regions 5’ to the Tbx20 coding sequence are directly 
involved in the positive and negative regulation of Tbx20 expression during early heart 
development. Moreover, only 334bp of upstream sequence is sufficient to drive the correct 
spatial cardiac-specific expression of Tbx20. 
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Signaling pathways upstream of the Tbx20 cardiac-specific enhancer are evolutionarily 
conserved 
To determine if the signal transduction pathways which function upstream of the 
Tbx20 334bp regulatory element are evolutionarily conserved, we analyzed the ability of X. 
tropicalis Tbx20 regulatory elements to direct cardiac expression in zebrafish.  We generated 
Tbx20(-2464) and Tbx20(-334)-EGFP fusion constructs flanked by I-SceI meganuclease sites 
(Figure 4.3A) and injected these transgenes together with the I-SceI meganuclease.  Injection 
of reporter constructs in this fashion yields relatively efficient, yet highly mosaic, transgene 
expression (13). Injection of the construct containing the Tbx20(-2464) element into 
zebrafish embryos at the one cell stage resulted in EGFP expression in 68% (129/190) of 
embryos analyzed at 48 hours post fertilization (hpf) with 43% of these embryos expressing 
the Tbx20 transgene in the heart (≥ 2 cells/heart, 56/129) (Figure 4.3C-D).  Expression 
elsewhere in the embryos was inconsistent and seen in areas including the yolk, head and 
trunk.  Injection of the smaller Tbx20(-334)-EGFP transgene also resulted in EGFP 
expression in the heart (Figure 4.3E-F).  Of embryos analyzed at 48 hpf, 74% (251/338) of 
the embryos expressed the transgene, while 18% (45/251) of these embryos expressed EGFP 
only in the heart (Figure 4.3E-F).  Again, expression outside of the heart was inconsistent.  
Therefore, these results show that the signaling pathway(s) utilized to drive cardiac 
expression of Tbx20 in vertebrates are evolutionarily conserved. 
 
Tbx20 expression is regulated by SMAD1/SMAD4 but not SMAD3 
To begin to determine the pathways which lead to the cardiac expression of Tbx20, 
we examined the 334bp minimal Tbx20 element by ConSite, Jaspar and Transfac software. 
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This analysis revealed putative transcription factor binding sites for a set of cardiac-specific 
transcription factors including SRF, NKX2.5, MEF2C, GATA4, SMAD1 and TBX5. To 
determine if any of these transcription factors could potentially regulate Tbx20 in vivo, we 
assayed their ability to activate transcription from cardiac-specific Tbx20 reporters.  To this 
end, Tbx20(-2464), Tbx20(-1483) and Tbx20(-334) luciferase reporter constructs were 
generated and tested for activation in transient transfections (Figure 4.4A-C). Of the potential 
transcription factors, only SMAD1, SRF, and the SRF co-factor myocardin, were capable of 
activating the Tbx20 reporters (Figure 4.4A-C).  Moreover, we observe that the 334bp 
reporter has a greater response to SMAD1 and SRF than the 1483bp or 2464bp elements 
suggesting sequences upstream of the 334bp element can attenuate the response to SMAD1 
and SRF.  
To more fully characterize the ability of the different members of the TGF-β family 
of signaling molecules to activate Tbx20, we tested the ability of SMAD1, a mediator of 
BMP signaling, SMAD3, a mediator of TGF-β/activin/nodal signaling, and the common 
SMAD, SMAD4, to activate Tbx20 reporters. We observed a dose-dependent activation of 
both the largest (-2464) and smallest (-334) Tbx20 regulatory elements when co-transfected 
with increasing amounts of SMAD1 (Figure 4.4D, G).  High doses of SMAD1 induced a 
greater than 5-fold activation of the reporter, suggesting that the Tbx20 regulatory element is 
responsive to the general BMP signaling pathway. Similarly, the Tbx20(-2464) and Tbx20(-
334) cardiac regulatory elements are activated by SMAD4 in a dose-dependent manner 
(Figure 4.4E, H).  In contrast, SMAD3 fails to activate any of the Tbx20 reporter constructs 
while it is still able to induce expression of the SMAD3 target SM22 (Figure 4.4F)(38). To 
confirm that TGF-β/Activin/Nodal signaling is not involved in Tbx20 induction, we also 
  82 
utilized the small molecule inhibitor SB431542 (Sigma) to block signaling through the 
SMAD3-mediated activin pathway.  In agreement with the lack of Tbx20 induction by 
SMAD3, treatment with SB431542 did not reduce the induction of the Tbx20 luciferase 
reporter by SMAD4, suggesting that Tbx20 activation occurs in a SMAD1-dependent, 
SMAD3-independent manner (Figure 4.4I). Upon further analysis, we observed that Tbx20 
reporters did not respond to myocardin in a dose specific fashion in vitro, nor did that 
mutation of a putative SRF binding site have any effect on Tbx20 reporter expression in vivo. 
Therefore, SRF and its co-factor myocardin were not analyzed in any further detail (data not 
shown).   
 
Tbx20 and SMAD1 co-localize during cardiac chamber formation 
Upon activation of the BMP signaling pathway SMAD1 is phosphorylated and 
translocates to the nucleus (reviewed in (23, 33)). To determine if SMAD1 is nuclear 
localized and co-expressed with Tbx20, and therefore could function endogenously to 
regulate Tbx20 expression, we determined the precise spatial and temporal expression of 
SMAD1 relative to Tbx20 during cardiac chamber formation. For these studies, serial 
sections of X. laevis hearts (stage 46) were examined by sectioned in situ hybridization for 
Tbx20 expression and the adjacent sections stained for SMAD1. Results from these studies 
show that Tbx20 is expressed throughout all cardiac tissue at stages of development 
corresponding to chamber formation (stage 46). Specifically, we observe Tbx20 expression in 
the anterior regions of the heart, including the truncus arteriosus and atria, in a pattern that 
overlaps markers of the myocardium, such as tropomyosin (Figure 4.5A, C, E). Tbx20 
expression is also seen in mid and posterior portions of the heart in tissues including the 
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ventricle and outflow tract (Figure 4.5B, D, F).  We observe an identical pattern of nuclear 
SMAD1 in adjacent sections. Thus, Tbx20 and SMAD1 appear to be co-localized throughout 
all cardiac tissue types along the anterior-posterior and dorsal-ventral axes of the heart.  
 
SMAD activation of Tbx20 occurs through direct binding of SMAD1 
SMAD proteins share two conserved Mad homology 1 (MH1) and Mad homology 2 
(MH2) domains, of which the MH1 domain has been shown to bind DNA in a sequence-
specific manner (16, 25). To identify the regions within the Tbx20 cardiac regulatory element 
that are directly bound by SMAD1, we conducted fluorescence polarization DNA-binding 
assays.  This technique can also be used to accurately determine the binding affinity of 
SMAD1 to the respective DNA sequence.  To this end, we tiled double stranded, 30 bp, 5’ 
carboxyfluorescein-labeled oligos covering the 334bp cardiac regulatory element overlapping 
by 15bp for full 2x coverage (Figure 4.6A).  Based on the premise that oligos tumble more 
slowly in solution when bound by protein as compared to unbound oligos, we combined 
fluorescent oligos with increasing concentrations of a full length GST-SMAD1 fusion protein 
to evaluate the changes in light depolarization, as anisotropy, using a PHERAstar microplate 
reader (BMG Labtechnologies, Durham, NC).  From the anisotropy data, we plotted binding 
curves and calculated dissociation constants (Kd) for each oligo interaction with SMAD1 
(Figure 4.6B).  As controls, we examined the binding of full length GST-SMAD1 to oligos 
containing known SMAD1 binding sequences (XVent) or known SRF binding sequences (8, 
18). From these studies, seven individual oligos were bound more strongly than the XVent 
control oligo (Kd= 7.83µM) based on two standard deviations and a 95.4% confidence level. 
We note that dissociation constants calculated in these studies vary from those previously 
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shown for protein-DNA interactions, however, this is likely a reflection of the salt 
concentration required for the GST-SMAD1 protein to remain in solution (32, 54). SMAD1 
bound oligo 8, covering bases -105 to -135, with the highest affinity (Kd=2.08µM).  
However, SMAD1 also bound six additional oligos (2, 6, 9, 13, 16, 19) with similar affinities 
(Kd=2.40µM to Kd=3.76µM)(Figure 4.6B).  Results from these studies show that SMAD1 
binds the Tbx20 cardiac regulatory element at 7 individual sites (Figure 4.6C-D) and suggest 
that these seven sites are high affinity binding sites. This therefore supports a biologically 
relevant interaction between SMAD1 and sequences contained in the Tbx20 reporter element 
(Figure 4.6B).  
Sequence analysis of the oligos bound by SMAD1 reveals two conserved, consensus 
SMAD binding sites with the sequences GTCT and CAGAC in oligos 16 and 8, respectively.  
We observe that one region containing a putative binding site failed to bind SMAD1 protein 
in vitro.  From this, we propose the presence of non-traditional SMAD binding elements 
between bases -15 and -45, -75 and -105, -120 and -150, -180 and -210, and -270 and -300. 
We further note that SMAD1 is capable of binding non-canonical sites with affinities equal 
to that of canonical sites.  
 
Canonical SMAD sites alone are not sufficient for SMAD1 response 
To determine the in vivo relevance of the canonical and non-canonical SMAD1 
binding sites we first mutated the two conserved SMAD1 canonical sites either individually, 
or in combination, in the context of both the 334bp and 2464bp regulatory elements, yet saw 
little effect on Tbx20 regulation in transcriptional assays or X. laevis transgenics (Figure 
4.7A-B, Data not shown).  To confirm and extend these findings, we generated additional 
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deletions of the 334bp element to 251bp. Thus, this reporter construct contains both 
canonical SMAD sites and all but one of the non-canonical sites. Similar to the Tbx20(-2464) 
or Tbx20(-334) regions, 251bp of Tbx20 upstream sequence is responsive to SMAD1/4 with 
the Tbx20(-251) reporter induced greater than 20-fold by 200ng SMAD4 (Figure 4.7C). We 
note that these inductions are higher than observed for Tbx20(-334) reporter and most likely 
result from the removal of a negative regulatory element between -334bp and -251bp. When 
introduced into X. laevis the Tbx20(-251) reporter is expressed in the heart and cement gland 
in a pattern similar to that of the Tbx20(-334) reporter, however we also note an increase in 
EGFP expression in non-cardiac tissues (Figure 4.7E-F). A further deletion of the all 
canonical and all but one non-canonical SMAD1/4 binding sites greatly diminishes 
SMAD1/4 responsiveness and results in non-specific expression of the reporter in transgenic 
X. laevis (Figure 4.7D, G-H). Finally, if we delete the 334bp minimal element in the context 
of the original Tbx20(-2464) cardiac reporter, both the response to SMAD1/4 in tissue culture 
assays and EGFP expression in transgenic X. laevis embryos are abolished (Figure 4.7I, Data 
not shown).   
Together, these data suggest that the 334bp region directly upstream of the Tbx20 
start site is both necessary and sufficient for cardiac expression of Tbx20 and that Tbx20 
cardiac expression is dependent on SMAD1/4 activity. These data further suggest that at least 
one SMAD1/4 response element is located between -81 and -1bp upstream of the Tbx20 
transcriptional start site and additional elements are located between -251 and -81bp 
upstream of the start site, strongly suggesting that Tbx20 expression in response to SMAD1/4 
requires a complement of canonical and non-canonical SMAD1/4 binding sites. 
 
  86 
DISCUSSION 
Studies of cardiac gene regulation have suggested that heart specific transcription is 
regulated temporally and spatially through a set of distinct modular cis-acting elements (42).  
Here we report the identification of a 334bp element from Xenopus that contains a series of 7 
high affinity SMAD1/4 binding sites that are necessary and sufficient for the evolutionarily 
conserved cardiac expression of Tbx20. Complementary to this finding, we have identified 
additional sequences that negatively attenuate the BMP/SMAD1 response. Taken together, 
these data strongly imply that BMP/SMAD1 signaling is necessary to maintain Tbx20 
expression during cardiac chamber formation. 
 
Tbx20 cardiac expression and canonical and non-canonical SMAD1 binding sites 
Our data demonstrate a requirement for a set of high affinity canonical and non-
canonical SMAD binding sites in the regulation of Tbx20 expression. Sequence analysis of 
the 334bp Tbx20 cardiac element reveals two conserved, consensus SMAD binding sites with 
the sequences GTCT and CAGAC. We have demonstrated that mutation of the SMAD1/4 
canonical binding sites either alone or in combination has little effect on the expression of 
Tbx20 either in vitro or in vivo, implying that it is the complement of canonical and non-
canonical SMAD1 binding sites which are required for the cardiac expression of Tbx20. 
Additionally, our results imply that the ability of SMAD1 to bind to DNA is not based on 
sequence alone. This is further supported by our observation that a region of the Tbx20 
minimal element containing a SMAD1/4 putative binding site failed to bind to SMAD1 
protein in vitro. Taken together with our data in zebrafish, our data support a model in which 
evolutionarily conserved gene regulation by BMP involves a combinatorial set of unique 
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SMAD binding elements of which individual elements differ in their contribution to the 
response to growth factor signaling, and therefore transcriptional output.  
Our findings that a complement of SMAD1/4 binding sties are required for Tbx20 
cardiac expression is broadly consistent with studies on two other BMP-responsive genes, 
XVent and Nkx2.5.  In the case of XVent, the early mesodermal expression is dependent on 
five putative SMAD1/4 binding sites while cardiac expression of Nkx2.5 is dependent on 12 
individual SMAD1/4 binding sites (2, 18, 29, 30). Similar to our findings, point mutations or 
deletions of multiple SMAD1/4 binding sties in the XVent promoter has no effect on SMAD 
responsiveness (18). However, the cardiac-specific expression of Tbx20 in cardiac tissue is 
unique in that, in the case of Nkx2.5, the cardiac specificity is mediated by a direct interaction 
between a SMAD1/SMAD4 complex and a member of the GATA transcription factor family 
(2). Although we have identified a GATA consensus site within the minimal Tbx20 cardiac 
element, none of the Tbx20 reporters respond to GATA4 (Figure 4.4), and deletion of the 
GATA site has no effect on cardiac-specific expression (Figure 4.7D). Thus, Tbx20 cardiac-
specific expression through the 334bp regulatory element, unlike that of Nkx2.5, appears to 
occur through a GATA-independent mechanism. The activation of cardiac gene expression 
via BMP signaling has also been shown to be dependent on additional cardiac transcription 
factors.  For example, the myocardin-dependent expression of cardiac genes is synergistically 
activated by the direct interaction of SMAD1 with myocardin (6).  However, our data with a 
large panel of cardiac transcription factors, demonstrate that with the exception of SRF, none 
of these factors could significantly induce Tbx20 expression in transient transcriptional 
assays.  We cannot formally rule out a potential role for SRF in Tbx20 expression, 
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particularly in regulating the levels of Tbx20; however, mutation of the SRF site had no 
effect on Tbx20 reporter expression in vivo (data not shown). 
 
Cardiac-specific Tbx20 expression 
What then regulates the cardiac specific expression of Tbx20? We note that SMAD1 
nuclear localization during heart development is temporally regulated. Based on this 
observation and our reporter analysis, we favor a model by which the complement of 
SMAD1/4 sites direct a broader pattern of expression in the embryo that is then restricted to 
the developing cardiac tissue by as of yet unidentified transcriptional repressors. This idea is 
supported by our observations that the SMAD1 and SMAD4 response of Tbx20 reporters is 
enhanced upon deletion of regions both outside and within the 334bp element and that, upon 
reduction of the 334bp Tbx20 regulatory element to 81bp, we observed a substantial increase 
in reporter expression in X. laevis transgenics in non-cardiac tissues. These findings are 
consistent with studies that have demonstrated that the BMP arm of the SMAD signaling 
pathway is associated with the regulation of genes involved in early heart development, while 
the TGF-β/activin/nodal arm of the SMAD pathway signals appear to drive cardiac 
regulation of factors associated with fibrotic, apoptotic and anti-hypertrophic events related 
to progression to heart failure (reviewed in (10)).  Additionally, BMP signals have been 
suggested to act as long-range diffusible morphogens originating from multiple locations in 
the embryo including the endoderm, ectoderm or cardiac cells themselves (37, 39, 41).  It is 
therefore interesting to speculate that the regulation of the novel 334bp Tbx20 cardiac 
element during late cardiogenesis is a result of a continued or second wave of BMP signaling 
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from the underlying endoderm, or from the myocardial cells themselves mediated by 
SMAD1/4.  
Although the SMAD1/4 sites are critical for the expression of Tbx20 during cardiac 
chamber formation, the element of Tbx20 that we have identified does not activate Tbx20 in 
other regions of the embryo where Tbx20 is endogenously expressed. Thus, our minimal 
Tbx20 element does not comprise all of the appropriate information for the complete 
expression pattern of Tbx20 and the early cardiac and neural elements of Tbx20 are yet to be 
identified. From this, and the modularity of the BMP/SMAD response elements that we have 
characterized, it appears that like Nkx2.5, the regulation of Tbx20 occurs in a modular 
manner. Finally, given that the minimal element that we have identified is required for 
expression of Tbx20 during cardiac chamber formation, and given the correlation between 
mutations in Tbx20 and human congenital heart disease (21), it will be interesting to 
determine if there exists an association between mutations in the Tbx20 minimal element and 
congenital heart disease and/or cardiac hypertrophy.  
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Figure 4.1.  A regulatory element 5’ to the Tbx20 genomic locus is sufficient to drive gene 
expression in the cement gland and heart.  A, Schematic representation of the X. tropicalis 
Tbx20 genomic locus.  X. tropicalis Tbx20 consists of 8 exons spanning approximately 20kB.  
The Tbx20 transcriptional start site is located 287bp upstream of the transcriptional start site 
in exon 1.  A putative cardiac regulatory element is located at the 5’ end of the Tbx20 locus 
(dashed box).  B, Schematic representation of the 2464bp region of the 5’ end of Tbx20 
cloned in frame to the EGFP reporter to examine its regulatory capacity in X. laevis 
transgenics.  C-F, EGFP expression is driven by 2464bp of the 5’ end of Tbx20 in the cement 
gland and heart of living X. laevis transgenic embryos.  Arrows point to the heart.  C, Ventral 
view of the anterior end of stage 46 sibling non-transgenic (left) or transgenic (right) 
embryos.  D, Fluorescent view of siblings in C.  E and F, Magnified view of the EGFP 
expression driven by the Tbx20 regulatory element in the cement gland (E) and heart (F) of 
the transgenic embryo in D.  Scale bar is equal to 500µm. 
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Figure 4.2.  A 334bp regulatory element recapitulates the endogenous expression of Tbx20 
throughout the X. laevis heart.  A deletion series of the 5’ regulatory element was created to 
determine a reduced element sufficient to drive EGFP transgene expression.  A, Schematic 
representation of the deletion series of Tbx20 elements fused to EGFP for X. laevis 
transgenesis.  B, E, H, Ventral view of the anterior regions of living stage 46 (late tadpole) X. 
laevis embryos (left) and siblings transgenic for constructs shown in A (right) under white 
light.  C, F, I Embryos as viewed under fluorescent light.  Green autofluorescence in the gut 
can be noted in both control and transgenic embryos. Arrows note the location of the heart. 
Scale bar is equal to 500µm. D, G, I Magnified views of the EGFP-expressing hearts of 
embryos in C, F and I demonstrating that EGFP expression in the heart is maintained under 
the control of a Tbx20(-334) element.  Transverse sections were cut through the embryos 
expressing Tbx20-EGFP shown in B-J, and expression of the Tbx20(-2459)-EGFP (K, L), 
Tbx20(-1483)-EGFP (M, N), and Tbx20(-334)-EGFP (O, P) transgenes is demonstrated by 
antibody staining for EGFP.  Anterior (K, M, O) and posterior (L, N, P) sections show EGFP 
transgene expression throughout the heart. Scale bar is equal to 100µm.  TA – truncus 
arteriosis, OFT – outflow tract, CA – carotid arch, V – ventricle, T – trabeculae, EC – 
endocardial cushion, PA – pulmocutaneous arch, SA – systemic arch, LA – left atrium, RA – 
right atrium 
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Figure 4.3.  X. laevis regulatory elements of Tbx20 are sufficient to drive EGFP reporter 
expression in the embryonic zebrafish heart.  A, Schematic representation of the XTbx20-
EGFP reporter constructs containing I-SceI meganuclease sites utilized in zebrafish.  B, D 
Lateral views of live zebrafish embryos at 48 hpf. injected with the 2464bp Tbx20-EGFP 
transgene (B) or 334bp transgene (D). C, E Injected embryos express EGFP in the heart 
(arrows).  Of embryos analyzed at 48 hpf, expression of EGFP in the heart was observed in 
22% (59/264) of embryos injected with the 2464bp transgene, and in 20% (17/89) of 
embryos injected with the 334bp transgene.  hpf – hours post fertilization 
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Figure 4.4.  XTbx20 5’ regulatory elements are activated by TGF-β/BMP signaling via 
SMAD1 and SMAD 4 but not SMAD3.  A-C, Luciferase reporters controlled by three Tbx20 
deletion elements were transfected into COS7 cells with a panel of cardiac factor expression 
plasmids.  Both the Tbx20(-2464) (D-E) and Tbx20(-334) (G-H) reporters are activated by 
SMAD1 and SMAD4 in a dose-dependent manner when transfected with increasing amounts 
of SMAD expression plasmid.  F, SMAD3 transfection does not induce the Tbx20(-2464) 
reporter, though the control SM22 reporter is dramatically induced.  I, Treatment of COS7 
cells with increasing doses of a small molecule inhibitor of activin signaling SB431542 does 
not affect the activation of the Tbx20(-334) plasmid by SMAD4.  Values are the fold increase 
in luciferase activity relative to that driven by the reporter alone.  Error bars represent the 
standard error of fold induction for three trials. 
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Figure 4.5.  XTbx20 is expressed throughout the myocardium and endocardium of the X. 
laevis heart.  A and B, Tbx20 is expressed in both the anterior and posterior regions of the X. 
laevis stage 46 heart.  Serial sections show that Tbx20 expression overlaps with that of the 
myocardial marker tropomyosin (C, D) and with SMAD1/5/8 expression in the endocardium 
(E, F) by immunohistochemistry.  C-F, Anti-tropomyosin (Tm) staining is labeled in green, 
anti-SMAD1/5/8 is labeled in red, and all nuclei are labeled with DAPI in blue. Scale bar is 
equal to 100µm.  TA-truncus arteriosus, OFT-outflow tract, LA-left atrium, V-ventricle 
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Figure 4.6.  SMAD1 potentially binds to seven regions within the 334bp Tbx20 regulatory 
element.  A, Double stranded, 5’ carboxyfluorescein-labeled, 30bp oligos designed for 2x 
coverage of the 334bp Tbx20 cardiac regulatory element for use in fluorescence polarization 
assays. B, Dissociation constants (Kd), standard deviation of three trials and nucleotide 
sequence for each oligo analyzed in fluorescence polarization studies (*indicates oligos 
bound by SMAD1). Kd values for 9 oligos are recorded as >7.42µM, as Kd  values 
significantly greater than the maximum SMAD1 concentration cannot be accurately 
calculated. C, Sequences of the minimal regions bound by SMAD1 on each of seven bound 
oligos. D, Schematic representation of the location of seven putative SMAD1 binding sites 
located within the 334bp cardiac regulatory element.
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Figure 4.7.  Multiple SMAD1 binding sites are involved in, and necessary for Tbx20 
regulation. Two conserved SMAD binding sites were identified within the 334bp regulatory 
element using the ConSite algorithm and mutated using site-directed mutagenesis in the 
context of the Tbx20(-2464)-EGFP or –luc reporter constructs (A), and the Tbx20(-334)-
EGFP or –luc constructs (B).    C, COS7 cells were transfected with a truncated region of the 
Tbx20 cardiac regulatory element retaining 251bp upstream of the transcriptional start site 
and increasing amounts of SMAD4 expression plasmid.  D, COS7 cells were then transfected 
with the Tbx20(-81) plasmid containing only 81bp upstream of the transcriptional start and 
increasing amounts of SMAD4.  Each additional deletion is activated by SMAD signaling in 
a dose-dependent manner.  Values represent fold luciferase activity relative to reporter 
plasmid alone. E-H, Tbx20(-251)-EGFP (E-F) or Tbx20(-81)-EGFP (G-H) reporter constructs 
were introduced into X. laevis transgenic embryos.  Transgenic embryos are located at the 
right of each image, while non-transgenic siblings are at the left.  E and G, Brightfield views 
of living stage 46 embryos.  F and H, EGFP expression of embryos in E and G. Arrows note 
the location of the heart. Scale bar is equal to 500µm. I, The 334bp regulatory element was 
eliminated from the 2464bp regulatory element to create Tbx20(-2464:-334)-luc and Tbx20(-
2464:-334)-EGFP constructs.  In COS7 cells, Tbx20(-2464)-luc, Tbx20(-334)-luc and 
Tbx20(-2464:-334)-luc were each co-transfected with 200ng Smad1 or Smad4 reporter 
constructs, demonstrating a reduction in Tbx20 activation and a necessity for the 334bp 
upstream element.  Fold induction reflects changes in induction relative to induction of the 
reporter alone, and error bars represent standard error of three replicates. 
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CHAPTER 5 
THE ROLE OF microRNA-1 AND -133 IN SKELETAL MUSCLE 
PROLIFERATION AND DIFFERENTIATION 
 
 
 
PREFACE 
 Chapter 5 focuses on the regulation and roles of two members of a newly 
characterized class of regulatory RNAs termed microRNAs, members of which are directly 
involved in the post-transcriptional regulation of gene expression.  Here, miRNA-1 and 
miRNA-133 are shown to be transcribed from the same loci while performing unique 
functions in early skeletal muscle proliferation and differentiation, the first evidence of its 
kind.  This suggests that miRNAs are key members of a transcriptional network that is 
involved in early muscle and embryonic development. 
 This work was previously published and represents a collaboration with Jian-Fu 
Chen, J. Michael Thomson, Qiulian Wu, Thomas E. Callis, Scott M. Hammond and Da-Zhi 
Wang.  The project was designed and developed in the lab of Dr. Da-Zhi Wang by Jian-Fu 
Chen and Dr. Da-Zhi Wang.  To contribute to this endeavor, I carried out the majority of the 
Xenopus studies and was an active participant in the writing of the manuscript and critical. 
 
Chen, J.F., E.M. Mandel, J.M. Thomson, Q. Wu, T.E. Callis, S.M. Hammond, F. L. 
Conlon, and D.Z. Wang.  The role of microRNA-1 and microRNA-133 in skeletal 
muscle proliferation and differentiation.  Nature Genetics 38(2):228-233. 
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SUMMARY 
 Understanding the molecular mechanisms that regulate cellular proliferation and 
differentiation is a central theme of developmental biology. MicroRNAs (miRNAs) are a 
recently discovered class of ~22-nucleotide regulatory RNAs that post-transcriptionally 
regulate gene expression (1, 2). Increasing evidence has pointed to the potential role of 
miRNAs in a variety of biological processes (6, 8, 9, 15, 27, 28). Here, we describe that 
miRNA-1 (miR-1) and miRNA-133 (miR-133), which are clustered on the same 
chromosomal loci, are transcribed together in a tissue-specific manner during 
development. miR-1 and miR-133 play distinct roles in modulating skeletal muscle 
proliferation and differentiation in cultured myoblasts in vitro and in Xenopus embryos 
in vivo. miR-1 promotes myogenesis by targeting histone deacetylase 4 (HDAC4), a 
transcriptional repressor of muscle gene expression. In contrast, miR-133 enhances 
myoblast proliferation by repressing serum response factor (SRF). The results reveal, 
for the first time, that two mature miRNAs, derived from the same miRNA polycistron 
and transcribed together, could perform distinct biological functions. Together, our 
studies suggest a molecular mechanism in which miRNAs participate in transcriptional 
circuits that control skeletal muscle gene expression and embryonic development. 
 
BACKGROUND, RESULTS AND DISCUSSION 
In order to understand the potential involvement of microRNAs (miRNAs) in skeletal 
muscle proliferation and differentiation, we analyzed the expression of miRNAs during 
skeletal muscle differentiation using the established microarray analysis (23). We chose to 
use C2C12 myoblasts because this line of cells faithfully mimics skeletal muscle 
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differentiation in vitro as myoblasts can be induced to become terminally differentiated 
myotubes when serum is withdrawn from the culture medium (3, 18, 22). We found that the 
expression of a fraction of the miRNAs examined was up-regulated in differentiated C2C12 
myoblasts/myotubes (Fig. 5.1a and Fig. S.5.1). The increase in expression of miR-1 and 
miR-133 in differentiated myoblasts was confirmed by Northern blot analysis (Fig. 5.1b and 
Fig. S.5.2).  
miR-1 and miR-133 are specifically expressed in adult cardiac and skeletal muscle 
tissues, but not in other tissues tested (Fig. 5.1c, Fig. 5.3)(13-15). However, little is known 
about the temporospatial distribution of specific miRNAs during mammalian development. 
We therefore examined the expression of miR-1 and miR-133 in mouse embryos and 
neonates. miR-1 and miR-133 are expressed at very low levels in the developing hearts and 
skeletal muscle of E13.5 and E16.5 embryos, (Fig. 5.1d and Fig. S.5.3). An increasing level 
of miR-1 and miR-133 expression was found in neonatal hearts and skeletal muscle, though 
it is still significantly lower than that of adults (Fig. 5.1e and Fig. S.5.3). These data are 
consistent with findings from zebrafish in which the majority of miRNAs are expressed 
relatively late during embryogenesis (26). 
Both miR-1 and miR-133 are clustered together on mouse chromosomes 2 (separated 
by 9.3 kb) and 18 (separated by 2.5 kb) (Fig. S.5.4)(14). We performed a Northern blot 
analysis using ~300 bp genomic probes including the miR-1 or miR-133 sequences (Fig. 
S.5.4). miR-1 and miR-133 probes from chromosome 18 detected a single primary transcript 
of ~ 6 kb from total RNAs isolated from heart and skeletal muscle (Fig. S.5.4 b and c), 
indicating that miR-1 and miR-133 are indeed transcribed together. While both miR-1 and 
miR-133 probes from chromosome 2 detected a transcript of ~ 10 kb from the heart and 
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skeletal muscle, the miR-133 probe also hybridized to two additional transcripts of ~ 4.5 kb 
and ~ 2.2 kb, while the miR-1 probe also detected a major transcript of ~ 6 kb (Fig. S.5.4 d 
and e), suggesting the potential involvement of post-transcriptional processing. Together, our 
data indicate that cardiac- and skeletal muscle-specific expression of miR-1 and miR-133 is 
dictated at the primary transcription step. 
We reasoned that the regulatory elements which control the transcription of both 
chromosome 2, and 18 miR-1 and miR-133 clusters are likely conserved. We therefore 
performed sequence analysis and identified a highly conserved region (~ 2 kb) which lies 
about 50 kb upstream of the miR-1/133 clusters on both chromosome 2 and 18 (Fig. S.5.5). 
When this genomic fragment from chromosome 2 was used to drive the expression of a 
dsRed reporter gene in transgenic Xenopus, we found cardiac- and skeletal-muscle specific 
expression of the transgene (Fig. S.5.5). 
To assess the function of miR-1 and miR-133 in skeletal muscle, we first attempted to 
overexpress miR-1 and miR-133 in mammalian cells. We tested and validated the expression 
and activity of both miRNAs using Northern blot analysis as well as miR-1 and miR-133 
“sensors”(19), in which the complementary sequences for miR-1 or miR-133 were cloned 
downstream of a dsRed coding sequence (Fig. S.5.6 and Data not shown). We transfected 
C2C12 myoblasts with miR-1 or miR-133 and then either maintained cells in growth medium 
(GM) or transferred them to differentiation medium (DM) after transfection. miR-1 strongly 
enhanced myogenesis as indicated by increased expression of both the early and late 
myogenic markers myogenin and myosin heavy chain (MHC), respectively, as well as other 
myogenic markers, including MyoD, Mef2,  and skeletal α-actin (Fig. 5.2, a-e, i, j and Table 
5.1). miR-1 induced myogenic marker gene expression in cells maintained in both the log-
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phase growth condition (Fig. 5.2c) and the differentiation condition (Fig. 5.2, d, e). 
Accelerated myogenic differentiation induced by miR-1 is also accompanied by a decrease in 
cell proliferation, as marked by a significant decrease in the expression of phospho-histone 
H3 (Fig. 5.2, c, e and Table 5.1). Of particular note, miR-1 induced myogenesis is specific, 
since overexpression of a GFP control or miR-208, which is not endogenously expressed in 
skeletal muscle cells, showed no effect (Fig. 5.2 a-e). Furthermore, mutations introduced into 
miR-1 “seed” sequences abolished its ability to activate myogenic gene expression (Fig. 5.2, 
d, e). In contrast, overexpression of miR-133 repressed the expression of myogenin and 
MHC (Fig. 5.2, a-e and Table 5.1) and promoted myoblast proliferation (Fig. 5.2, c, e and 
Table 5.1). Again, the effect of miR-133 on myoblasts proliferation is specific, as controls 
showed no effect and mutation introduced abolished the function of miR-133 (Fig. 5.2, a-e, 
j). 
We performed the reciprocal experiment wherein we transfected C2C12 myoblasts 
with the miR-1 or miR-133 2’-O-methyl antisense inhibitory oligos (or control GFP and 
miR-208), which have been shown to inhibit the function of miRNAs(10, 21). Cells 
transfected with the miR-1 inhibitor showed inhibition of myogenesis and promotion of 
myoblast proliferation, as indicated by a decrease in myogenic markers and an increase in 
phospho-histone H3 (Fig. 5.2, f-i and Table 5.1). Consistent with the role of miR-133 in 
promoting myoblast proliferation and repressing differentiation, inhibition of miR-133 
caused an opposing effect, where myogenesis was enhanced and cell proliferation repressed 
(Fig. 5.2, f-j and Table 5.1).  In contrast, control 2’-O-methyl inhibitors showed no effects 
(Fig. 5.2, f-j). We conclude that miR-1 and miR-133 have distinct roles in skeletal muscle 
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proliferation and differentiation: miR-1 promotes myoblast differentiation, whereas miR-133 
stimulates myoblast proliferation. 
Both miR-1 and miR-133 have been found in most animal species, from Drosophila 
to human, suggesting they are evolutionary conserved. To test the effects of miR-1 and miR-
133 on skeletal muscle and heart development in vivo, we identified copies of miR-1 and 
miR-133 in Xenopus and tested their function through mis-expression. Introduction of miR-1 
at the one cell stage leads to a dramatically shortened axis with accompanying reduction in 
anterior structures and an increase in body size along the dorsal-ventral axis compared to 
either uninjected or miGFP injected controls (n > 45, two independent experiments) (Fig. 
5.3).  Although somites formed in miR-1 injected embryos (Fig. 5.3), whole-mount antibody 
staining and serial sectioning reveal the tissue is highly disorganized and fails to develop into 
segmented structures (Fig. 5.3, e, f, j). Cardiac tissue is completely absent as judged by 
histology, tropomyosin staining (Fig. 5.3, f, j) and cardiac actin staining (Data not shown). In 
addition to these defects, there is a dramatic decrease in phospho-histone H3 staining (Fig. 
5.3, i-k), consistent with the essential role of miR-1 in regulating muscle cell proliferation 
and differentiation. Although mis-expression of miR-133 also leads to a reduction in anterior 
structures and defects in somite development, in contrast to miR-1, there is only a modest 
reduction in anterior-posterior length and somatic defects are most severe in the more 
anterior or posterior aspects of the embryo where somites fail to form (Fig. 5.3, g, h). In 
addition, cardiac tissue frequently forms in miR-133 embryos, though it is highly 
disorganized and fails to undergo cardiac looping or chamber formation (Fig. 5.3, g, h, k and 
Data not shown). Collectively, these data suggest that the correct timing and levels of both 
miR-1 and miR-133 are required for proper skeletal muscle and heart development.  
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To identify target genes that could mediate the observed effects of miR-1 and miR-
133 on skeletal muscle proliferation and differentiation, we examined predicted target genes 
for these two miRNAs. Multiple computational/bioinformatics-based approaches have been 
applied to predict targets for miRNAs and numerous potential targets have been suggested 
(11, 12, 16). Strikingly, many transcription factors have been suggested to be the targets for 
miRNAs, raising the possibility that miRNAs might be involved in transcriptional regulation 
of gene expression. Among the predicted miR-1 targets, HDAC4 has previously been shown 
to inhibit muscle differentiation and skeletal muscle gene expression, mainly by repressing 
MEF2C, an essential muscle-related transcription factor (18, 20). HDAC4 contains two 
naturally occurring putative miR-1 sites at its 3’ UTR, which are evolutionarily conserved 
among vertebrate species (Fig. S.5.7). Similarly, two conserved miR-133 binding sites are 
found in the 3’ UTR of the mammalian SRF gene (Fig. S.5.7), which has been shown to play 
an important role in muscle proliferation and differentiation in vitro and in vivo (17, 22, 25).  
We fused the 3’ UTRs of mouse SRF and HDAC4 to a luciferase reporter gene and 
transfected these constructs along with transfection controls into mammalian cells. Ectopic 
overexpression of miR-1 strongly repressed a HDAC4 3’ UTR luciferase reporter gene, 
whereas miR-133 inhibited the expression of a SRF 3’ UTR luciferase reporter gene (Fig. 
5.4a). In contrast, mutations introduced into miR-1 or miR-133 “seed” sequences abolished 
such repression, indicating the specificity of the action (Fig. 5.4a).  
When the above reporters were transfected into C2C12 myoblasts and luciferase 
activity measured before and after the induction of cell differentiation, we found that the 
reporter activity was dramatically repressed in differentiated cells (Fig. 5.4b), indicating that 
increased levels of endogenous miR-1 and miR-133 inhibited the reporter gene. The effects 
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and specificity of endogenous miR-1 and miR-133 were monitored by the miRNA “sensor” 
(Fig. S.5.6). In contrast, the luciferase activity of the MCK-luc reporter, an indicator of 
muscle differentiation, was increased in differentiated muscle cells (Fig. 5.4b). Furthermore, 
overexpression of miR-1 led to the down-regulation of endogenous HDAC4 protein in 
C2C12 cells in both the growth condition (Fig. 5.4c) and differentiation condition (Fig. 5.4e), 
whereas miR-133 repressed the expression of endogenous SRF proteins (Fig. 5.4, c, e). In 
contrast, the mRNA levels of SRF and HDAC4 were not altered by those miRNAs (Fig. 
5.4d), supporting the notion that miRNAs repress the function of their target genes mainly by 
inhibiting translation. When 2’-O-methyl-antisense oligos against miR-1 or miR-133 were 
applied, they relieved repression exerted on the protein levels of HDAC4 or SRF, 
respectively (Fig. 5.4g), with no effect on their mRNA levels (Fig. 5.4f). To further verify 
that HDAC4 and SRF are cognate targets for miR-1 or miR-133 in regulating skeletal muscle 
gene expression, we tested whether co-transfecting expression plasmids for SRF or HDAC4 
could “suppress” miRNA-mediated myogenesis. Indeed, as shown in Fig. 5.4h, 
overexpression of SRF partially reversed myogenic gene repression induced by miR-133. In 
contrast, HDAC4 counteracted the effects of miR-1 on skeletal muscle gene expression (Fig. 
5.4h). Consistent with the potential involvement of HDAC4 and SRF in miR-1 and mir-133-
dependent skeletal muscle proliferation and differentiation, endogenous HDAC4 and SRF 
protein levels were down-regulated in differentiated C2C12 cells, with a concomitant 
increase in expression of myogenic differentiation markers and a decrease in expression of 
the mitotic index marker phospho-histone H3 (Fig. 5.4i and Fig. S.5.2d). Decreased 
expression of SRF and HDAC4 proteins was accompanied by an increase expression of miR-
1 and miR-133 (compare Fig. 5.4i with Fig. 5.1b). Together, these data demonstrate that 
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miR-1 and miR-133 specifically repress HDAC4 and SRF protein levels, respectively, which 
in turn, contributes to (at least in part) the regulatory effects of those miRNAs on myoblast 
proliferation and differentiation. 
We characterized cardiac- and skeletal muscle-specific miR-1 and miR-133 and have 
shown their essential function in controlling skeletal muscle proliferation and differentiation. 
Most importantly, we found that miR-1 and miR-133, which are clustered on the same 
chromosomal loci and transcribed together as a single transcript, become two independent, 
mature miRNAs with distinct biological functions achieved by inhibiting different target 
genes. This implicates the involvement of miRNAs in complex molecular mechanisms. 
Interestingly, while the tissue-specific expression of miR-1 and miR-133 is controlled by 
myoD and SRF (28), SRF expression is repressed by miR-133. Therefore, these findings 
reveal a negative regulatory loop in which miRNAs participate in regulatory pathways to 
control cellular proliferation and differentiation (Fig. 5.5). It will be interesting, for the 
future, to determine whether miR-1 and miR-133 are involved in cardiac- and skeletal 
muscle-related human diseases. 
 
MATERIALS AND METHODS  
MicroRNA expression analysis by microarray 
Total RNA was isolated from C2C12 cells cultured in growth medium (GM) consisting of 
DMEM (Sigma) with 10% fetal bovine serum (FBS) (Sigma) and 1% penicillin/streptomycin 
(Invitrogen) or differentiation medium (DM) consisting of DMEM (Sigma) with 2% horse 
serum (Sigma) at different time points (day 0, 1, 3, and 5 with the first day transferring into 
DM counted as day 0). Microarray hybridization was performed and data analyzed as 
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described(23). Briefly, 2.5 ug isolated RNA was labeled with 5'-phosphate-cytidyl-uridyl-
Cy3-3' (Dharmacon) using RNA ligase and hybridized with 0.5 mM mixture of 
oligonucleotide probes for 124 microRNAs labeled with Alexa 647 (Cy5) in disposable 
chambers from MJ Research (part number SLF-0601). Normalized log (base 2) data was 
hierarchically clustered by gene and is plotted as a heat map.  The range of signal was from –
4 fold to +4 fold. Yellow denotes high expression and blue denotes low expression, relative 
to the median.  
 
Northern blot analysis 
Total RNA was extracted from C2C12 cells, mouse embryonic or adult tissue using Trizol 
Reagent (Invitrogen). For Northern blot analysis of miRNA, PEG was applied to remove 
large sized RNAs. Briefly, 30 µg of each total RNA sample were mixed 1:1 with 5X PEG 
solution and placed on ice 10 min. After 10 min centrifuging at maximum speed at 4°C, the 
supernatant was transferred to a fresh tube. RNAs were then precipitated by adding 2.5 
volumes of 100% EtOH and centrifuged 30 min at maximum speed. Northern blot analysis 
for miRNAs was performed as described (14). miR-1 and miR-133 oligonucleotide 
sequences used as probes were listed in Table S.5.1. Northern blot analysis was used to 
detect primary transcripts of miRNAs and performed as described(24), using 20 µg of total 
RNA from each sample. Genomic fragments for miR-1 and miR-133 were PCR-cloned and 
serve as probes. 
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Cloning and expression of miR-1 and miR-133 
Genomic fragments for miR-1 and miR-133 precursors from mouse chromosomes 2 and 18 
(ch 2 or ch 18) were PCR amplified using mouse genomic DNA as a template (for PCR 
primers, see Table S.5.1). The PCR products were cloned into the pDNA(+)3.1 vector 
(Invitrogen) and the expression of miRNAs was determined by transfecting expression 
vectors into mammalian cells (COS7, 10T1/2 or C2C12) and detected by Northern blot 
analysis. 
 
Cell culture, in vitro myogenesis differentiation and luciferase reporter assay 
C2C12 myoblast cells were cultured and myogenesis induced as described (18). Transient 
transfection luciferase reporter assays were performed as described (18, 24).miRNA duplexes 
and 2’-O-methyl antisense oligoribonucleotides for miR-1, miR-133, miR-208 and GFP were 
purchased from Dharmacon (see Table S.5.1 for sequences). They were introduced into 
mammalian cells using either Lipofectamin (Invitrogen) transfection (200 nM) or 
eletroporation using Amaxa Nucleofector system (5 µg).  
For 3’ UTR-luciferase reporter construction, the multiple cloning site of the pGL3-Control 
Vector (Promega) was removed and placed downstream of the luciferase gene. 3’ UTRs for 
mouse HDAC4 and SRF were PCR amplified and cloned into the modified pGL3-Control 
Vector to result in the constructs SRF-3’UTR and HDAC4-3’UTR (see Table S.5.1 for PCR 
primer sequences). Luciferase reporter assays were performed as described (24). 
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Western blot and immunostaining 
Western blots were performed as described (5). The following antibodies were used: Anti- 
myogenin, SRF, MEF2, HDAC4 and β-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA); 
phospho-histone H3 (Upstate Biotechnology, Lake Placid, NY). The MF20 antibody, which 
recognizes striated muscle-specific MHC, was obtained from the DSHB (University of Iowa, 
Iowa City, IA). For immunostaining, treated C2C12 cell in 12-well plates were fixed with 
4% formaldehyde for 5 min at 37°C and changed to 0.1% NP40/PBS solution for 15 min at 
RT. Primary antibodies were incubated in 0.1% NP40-PBS with 3% BSA for 2 hr in the 
following concentration: anti-myogenin (1: 20 dilution), anti-phospho-histone H3 (1:100 
dilution), MF20 (1:10 dilution). Secondary antibodies fluorescein anti-mouse/rabbit (1:100 
dilution, Vector laboratories, Inc) were adding in 0.1% NP40-PBS with 3% BSA for 1 hr at 
37°C. DAPI was added in for 5 min at RT. After several wash with PBS, cells were subjected 
to fluorescence microscopy observation. Ten fields that cover the whole well were picked 
and green fluorescence positive cells and total cells with DAPI staining were counted for 
each well, respectively.  
 
RT-PCR analysis 
RT-PCR was performed essentially as described (5). Total RNA were extracted from C2C12 
cells using Trizol Reagent (Invitrogen), and 2.0 µg aliquots were reverse transcribed to 
cDNA using random hexamers and MMLV reverse transcriptase (Invitrogen). For each case, 
2.5% cDNA pool was used for amplification and PCR were performed for 24–28 cycles.  
Sequences for PCR primers can be found in Table S.5.1. 
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Xenopus embryo injections and transgenesis 
Standard methods were utilized in obtaining and culturing Xenopus laevis embryos. DNA 
constructs were linearized with Kpn I and transgenic embryos were generated according to 
the methods described by Kroll & Amaya (13). Expression of the transgene was analyzed 
under a Leica MZFLIII microscope. Preparation and injection of Xenopus with miRNAs was 
carried out essentially as previously described (7). However, RNA was not capped prior to 
injection. Whole-mount immunohistology analysis was carried out as described (4). 
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Figure 5.1. Expression of miR-1 and miR-133 in cardiac and skeletal muscle during 
development. (a) miRNA array expression data from C2C12 myoblasts cultured in growth 
medium (GM) or in differentiation medium (DM) for 0, 1, 3 and 5 days, respectively. 
Normalized log (base 2) data was hierarchically clustered by gene and is plotted as a heat 
map.  The range of signal was from –4 fold to +4 fold. Yellow denotes high expression and 
blue denotes low expression, relative to the median and only the miRNA nodes that are up-
regulated in differentiation medium are shown. (b) Northern blot analysis of the expression 
of miR-1 and miR-133 using total RNA isolated from C2C12 myoblasts cultured in GM or in 
DM for 0, 1, 3 and 5 days, respectively. tRNAs were used as a loading control. (c) Northern 
blot analysis of the expression of miR-1 and miR-133 in adult mouse tissues. (d) Northern 
blot analysis of the expression of miR-1 and miR-133 in embryonic day 13.5 (E13.5) and 
16.5 (E16.5) mouse tissues. (e) Northern blot analysis of the expression of miR-1 and miR-
133 in neonatal mouse tissues. Same amount of total RNAs from adult heart and skeletal 
muscle were loaded into blots to serve as a comparison to embryonic and neonate RNA (d, 
e).
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Figure 5.2. Regulation of myoblast proliferation and differentiation by miR-1 and miR-
133. C2C12 myoblasts cultured in growth medium (GM) were electroporated with double-
stranded miRNA duplexes for miR-1, miR-133, and GFP as a control.  (a to e) Cells were 
continuously cultured in GM for 24 hr after transfection, then transferred to differentiation 
medium (DM) for (a) 12 hr before immunostaining for myogenin or (b) 36 hr before 
immunostaining for MHC. C2C12 myoblasts cultured in GM were electroporated with 
double-stranded miRNA duplexes for miR-1, miR-133 (or their mutants as indicated), or 
miR-208 and GFP as controls and cultured for 24 hr before: (c) Western blotting using 
indicated antibodies;  (d) cells were transferred to DM for 24 hr and RT-PCR for the 
indicated genes were performed; (e) cells were transferred to DM for 24 hr and Western 
blotting using the indicated antibodies. (f to h) C2C12 myoblasts cultured in GM were 
electroporated with 2’-O-methyl antisense oligonucleotide inhibitors for miR-1, miR-133 or 
miR-208 and GFP as cotrols. Cells were cultured in GM for 24 hr after transfection then 
transferred into DM for: (f) 12 hr before immunostaining for phospho-histone H3; (g) 24 hr 
before performing RT-PCR for the indicated genes;  (h) 24 hr before Western blotting using 
indicated antibodies. (i and j) C2C12 myoblasts cultured in GM were electroporated with 
either the miRNA duplexes or 2’-O-methyl antisense oligonucleotide inhibitors as indicated. 
Cells were cultured in GM for 24 hr after transfection, then transfer into DM for 12 hr before 
immunostaining for myogenin (i) or phospho-histone H3 (j). Positive stained cells were 
counted and data are presented as the expression level relative to a GFP control (100%).  
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Table 5.1. Effect on myogenic proliferation and differentiation by miR-1 and miR-133 
overexpression and knock down. C2C12 myoblasts cultured in growth medium (GM) were 
electroporated with double-stranded miRNA duplex or 2’-O-methyl antisense oligos for miR-
1, miR-133 or GFP as a negative control. 36 hr later, GM was replaced with differentiation 
medium (DM) for 8, 12 and 24 hr and cells were fixed for immunohistochemistry analysis 
using antibodies against myogenin, phospho-histone H3 and Myosin heavy chain (MHC). 
Positive cells were counted out of 5000 DAPI staining cells from a randomly chosen field. 
Assays were performed three times independently with comparable results.
GFP 172 100% 93 100% 135 100% 118 100% 137 100% 22 100%
miR-1 206 121% 230 247.30% 93 68.90% 251 212.70% 76 55.50% 56 254.50%
miR-133 89 51.70% 68 73.10% 168 124.40% 93 78.80% 201 146.70% 12 54.50%
2’-O-
methyl-
GFP
146 100% 145 100% 172 100% 348 100% 207 100% 22 100%
2’-O-
methyl-
miR-1
120 82.20% 98 67.60% 214 124.40% 299 85.90% 283 136.70% 18 81.80%
2’-O-
methyl-
miR-133
205 140.40% 211 145.50% 107 62.20% 498 143.10% 191 92.30% 44 200%
Relative 
to 
control
MHC 
positive 
cells
Relative 
to 
control
Myogenin 
positive 
cells
Myogenin 
positive 
cells
Myogenin 
positive 
cells
DM (8 hr) DM (12 hr) DM (24 hr)
Treatment
Relative 
to 
control
Relative 
to 
control
Phospho-
H3 positive 
cells
Relative 
to 
control
Relative 
to 
control
Phospho-
H3 positive 
cells
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Figure 5.3. Control of cardiac and skeletal muscle development by miR-1 and miR-133 
in vivo. Top panels: Xenopus embryos derived from uninjected (a and b), GFP RNA control-
injected (c and d), miR-1-injected (e and f), or miR-133-injected (g and h) embryos stained 
with anti-tropomyosin and shown at stage 32 under brightfield (a, c, e, g) or fluorescence (b, 
d, f, h). Note the lack of staining for heart tissue (H, arrows) and disruption of segmented 
somites (S, arrows) in f and h. Bottom panels: Transverse sections of Xenopus embryos 
corresponding to the position of the heart at stage 32 from uninjected (i), miR-1 injected (j), 
or miR-133 injected (k) embryos stained with anti-tropomyosin to visualize somites (S, 
arrows) and cardiac tissue (H, arrows), and anti-phospho-histone H3 (red) to visualize cells 
in S phase. Each set of injections was conducted at least twice independently, and the 
phenotype was observed in at least 90% of a minimum of 50 embryos scored by whole 
mount immunostaining. 
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Figure 5.4. Identification of miR-1 and miR-133 target genes in skeletal muscle. (a) 
Repression of SRF and HDAC4 3’UTRs by miR-133 and miR-1. Luciferase reporters 
containing either miR-133 complementary sites from mouse SRF 3’ UTR (SRF-3’-UTR), 
miR-1 complementary sites from mouse HDAC4 3’ UTR (HDAC4-3’-UTR) or the perfect 
antisense sequences of miR-133 (miR-133-luc) or miR-1 (miR-1-luc) were co-transfected 
with the indicated miRNA expression vectors or their mutants. Luciferase activity was 
determined 48 hr after transfection. Data represent the mean + s.d. from at least three 
independent experiments in duplicate (* P < 0.05). (b) SRF-3’-UTR, HDAC4-3’-UTR, and 
MCK-luc luciferase reporters were transfected into C2C12 myoblasts. Cells were maintained 
in GM for 24 hr (GM) or transferred into DM for 1 day (DM1) or 3 days (DM3) before 
luciferase activity was determined. (c to e) C2C12 myoblasts cultured in GM were 
electroporated with indicated double-stranded miRNA duplexes (or their mutants), or miR-
208 and GFP as controls. Cells were cultured in GM for 24 hr after transfection before: (c) 
Western blotting using anti-SRF and anti-HDAC4 antibodies; (d) cells were transferred into 
DM for 24 hr and RT-PCR for the indicated genes performed; (e) cells were transferred into 
DM for 24 hr and Western blotting using indicated antibodies. C2C12 myoblasts cultured in 
GM were electroporated with indicated 2’-O-methyl antisense oligonucleotide inhibitors.  (f 
and g) Cells were cultured in GM for 24 hr after transfection, then transferred into DM for 24 
hr before: (f) RT-PCR for the indicated genes performed; (g) Western blotting using 
indicated antibodies. (h) C2C12 myoblasts cultured in GM were electroporated with 
indicated double-stranded miRNA duplexes or/and expression plasmids for SRF or HDAC4, 
as indicated. Cells were cultured in GM for 24 hr after transfection. Western blotting 
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performed 24 hr after transfer into DM using indicated antibodies. (i) C2C12 myoblasts were 
cultured in GM or DM for 0, 1, 3 or 5 days. Western blotting using indicated antibodies.  
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Figure 5.5. Model for miR-1 and miR-133-mediated regulation of skeletal muscle 
proliferation and differentiation. 
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Figure S.5.1. miRNA array analysis of C2C12 cells.  miRNA array expression data from 
C2C12 myoblasts cultured in growth medium (GM) or in differentiation medium (DM) for 0, 
1, 3 and 5 days, respectively. Normalized log (base 2) data was hierarchically clustered by 
gene and is plotted as a heat map. The range of signal was from –4 fold to +4 fold. Yellow 
denotes high expression and blue denotes low expression, relative to the median.
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Figure S.5.2. Expression of miR-1, miR-133 and skeletal muscle 
differentiation marker genes in C2C12 cells. (a and b) Northern blot analysis of the 
expression of miR-1 (a) and miR-133 (b) using total RNA isolated from C2C12 myoblasts 
cultured in GM or in differentiation medium (DM) for 0, 1, 3 and 5 days, respectively. Both 
mature miRNAs and their precursors (Pre) are indicated. tRNAs were used as a loading 
control. (c) Semi-quantative RT-PCR analysis of skeletal muscle differentiation marker 
genes. GAPDH was used as a control for equal loading. (d) Expression of skeletal muscle 
differentiation markers. C2C12 myoblasts were cultured in growth medium (GM) or in 
differentiation medium (DM) for 0, 1, 3 and 5 days, and Western blots performed with cell 
extracts using the indicated antibodies. β-tubulin serves as a loading control.
  132 
 
 
 
 
  133 
Figure S.5.3. Expression of miR-1 and miR-133 in cardiac and skeletal muscle in adult 
mice and throughout development. Northern blot analysis of the expression of miR-1 (a) 
and miR-133 (d) in adult mouse tissues. Northern blot analysis of the expression of miR-1 
(b) and miR-133 (e) in embryonic day 13.5 (E13.5) and 16.5 (E16.5) mouse tissues. Same 
amount of total RNA from adult heart and skeletal muscle was also loaded in the blot to 
serve as a comparison. Northern blot analysis of the expression of miR-1 (c) and miR-133 (f) 
in neonatal mouse tissues. Same amount of total RNA from adult heart and skeletal muscle 
was also loaded in the blot to serve as a comparison. Both mature miRNAs and their 
precursors (Pre) are indicated. tRNAs were used as a loading control.
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Figure S.5.4. Expression of miR-1 and miR-133 primary transcripts in 
cardiac and skeletal muscle. (a) Diagram showing miR-1 and miR-133 genes clustered 
on mouse chromosomes 2 and 18. Probes used for Northern blots in b through e are 
noted. (b - e) Northern blot analysis of the expression of primary transcripts for miR-1 
(c, e) and miR-133 (b, d) from chromosome 2 (d, e) and chromosome 18 (b, c). 20 µg of 
total RNA from the indicated adult mouse tissues was used. 
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Figure S.5.5. A miR-1 and miR-133 enhancer directs reporter gene 
expression in cardiac and skeletal muscle. Genomic DNA sequences of miR-1/133 
enhancer from mouse chromosome 2. A putative MEF2 site and CArG box are marked 
out, and mutations introduced into these sites are indicated (upper panel). (a) Xenopus 
laevis transgenic for mouse miR-1 and miR-133 genomic sequence linked to dsRed 
shows somite (S, arrows) expression at stage 28. (b) Transgenic (Tg) Xenopus laevis 
carrying a miR-1 and miR-133-containing transgene at stage 46 (lower embryo) and 
negative control (non-transgenic, Ct, upper embryo) under bright field. (c) Same embryos 
as b under fluorescence. (d) High power magnification of transgenic embryo in panel g 
under bright field and under fluorescence (e) showing expression of the trangene in the 
heart (H, arrows) and branchial arches (BA, arrows). (f) High magnification of stage 46 
transgenic embryo showing expression of the transgene in the somites (S, arrows). 
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Figure S.5.6. Repression of a miR-133 sensor by miR-133 in C2C12 
cells. C2C12 cells stably expressing the miR-133 sensor were transfected with expression 
vectors for GFP (control), wild –type miR-133 (miR-133), mutant miR-133 (miR- 
133mut) in which the “seed” sequence has been mutated, or a combination of miR-133 
expression vector and 2’-O-methyl antisense oligos (miR-133 + 2’-O-methyl). Cells were 
transferred into differentiation medium for 12 hr and images were obtained using 
phasecontrast (P/C) (a, b, c, d) or fluorescence to show expression of the dsRed reporter gene 
(e, f, g, h). Cells from each condition were harvested and the expression of the dsRed 
reporter gene was quantified using FACS analysis (lower panels). Red line denotes 
autofluorescein of the cell and green line indicates the ds-Red expression.
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Figure S.5.7. Sequences of the miR-1 and miR-133 target sites in the 3’ UTR of HDAC4 
and SRF genes. Upper panel: HDAC4 3’ UTR sequences from conserved vertebrate species 
and their alignment with miR-1 and miR-206. Lower panel: SRF 3’ UTR sequences from 
human and rat and their alignment with miR-133. Conserved nucleotide sequences are listed 
in upper case.
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Table S.4.1 Sequences of oligonucleotides used in this study. 
Name                       Sequence 
miR-1 probe  TACATACTTCTTTACATTCCA 
miR-133 probe  ACAGCTGGTTGAAGGGGACCAA 
miR-133a-1-up  CATGTGACCCCTCACACACA 
miR-133a-1-down  ACAAGGGGAGCCTGGATCCC 
miR-133a-2-up  GGACATATGCCTAAACACGTGA 
miR-133a-2-down  GAAACATCTTTATCCAGTTT 
miR-1-2-up   AGACTGAGACACAGGCGACACC 
miR-1-2-down  TGCCGGTCCATCGGTCCATTGC 
miR-1-1-up   CACTGGATCCATTACTCTTC 
miR-1-1-down  TTGGAATGGGGCTGTTAGTA 
miR-1mut-up   TGAACATTCAGTGCTATAAAGAAGTATGTATTTTGGGTAGGTA 
miR-1mut-down  TACCTACCCAAAATACATACTTCTTTATAGCACTGAATGTTCA 
miR-133mut-up  AATCGCCTCTTCAATGGATTTGTCAACCAGCTGTAGCTATGCATTGAT 
miR-133mut-down  ATCAATGCATAGCTACAGCTGGTTGACAAATCCATTGAAGAGGCGATT 
miR-1 duplex   UGGAAUGUAAAGAAGUAUGUA 
                             CAUACUUCUUUACAUUCCAUA 
miR-1-mut duplex  UUAACCAUAAAGAAGUAUGUA 
                                     CAUACUUCUUUAUGGUUAAUA 
miR-133 duplex  UUGGUCCCCUUCAACCAGCUGU 
                                 AGCUGGUUGAAGGGGACCAAAU 
miR-133-mut duplex  UCAAGUAACUUCAACCAGCUGU 
                                          AGCUGGUUGAAGUUACUUGAAU 
miR-208 duplex  AUAAGACGAGCAAAAAGCUUGU 
                                 AAGCUUUUUGCUCGUCUUAUAC 
GFP duplex   AACUUCAGGGUCAGCUUGCCUU 
                         GGCAAGCUGACCCUGAAGUUGG 
2'-O-methyl-miR-1  AAAUACAUACUUCUUUACAUUCCAUAGC 
2'-O-methyl-miR-133  AGCUACAGCUGGUUGAAGGGGACCAAAUCCA 
2'-O-methyl-miR-208  GACCAACAAGCUUUUUGCUCGUCUUAUACGUG 
2'-O-methyl-GFP  AAGGCAAGCUGACCCUGAAGUU 
HDAC4-UTR-up  CAGCACTGGTGATAGACTTGG 
HDAC4-UTR-down  CTTAAGAATAAGTTCAATAAGAC 
SRF-UTR-up   AGATATGGGGGCTTGTGCCC 
SRF-UTR-down  CTGGGAGAAAGGGGGTAGAC 
Myogenin F   TGGAGCTGTATGAGACATCCC 
Myogenin R   TGGACAATGCTCAGGGGTCCC 
MyoD F   GCAGGCTCTGCTGCGCGACC 
MyoD R   TGCAGTCGATCTCTCAAAGCACC 
Skeletal α-actin F  CAGAGCAAGCGAGGTATCC 
Skeletal α-actin R  GTCCCCAGAATCCAACACG 
MEF2D F   CAAGCTGTTCCAGTATGCCAG 
MEF2D R   AAGGGATGATGTCACCAGGG 
HDAC4 F   GAGAGAATTCTGCTAGCAATGAGCTCCCAA 
HDAC4 R   GAGACTCGAGCTATGCAGGTTCCAAGGGCAGTGA 
SRF F    GTCCCCATGCAGTGATGTATG 
SRF R   GTAGCTCGGTGAGGTTGCTG 
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CHAPTER 6 
 
GENERAL DISCUSSION 
 
 
 
One of the most vital challenges in the field of cardiovascular development, and in 
developmental biology in general, is to define the precise mechanisms governing the 
restricted spatial and temporal expression of developmental genes.  It is becoming clear, 
however, that complex regulatory networks, the combinatorial interactions of transcription 
factors, and cis-acting regulatory elements throughout the genome, are all key to the control 
of this regulation and have direct impacts on human disease.  In order to fully address these 
questions, it will be imperative to take a two-pronged approach by which the regulatory 
elements of individual genes as well as larger signaling networks as a whole are examined in 
tandem, as well as to work to further develop the model systems available for such studies.  
The work described in this dissertation examines the connection between specific 
transcription factors and human disease, begins to characterize the transcriptional regulation 
of the cardiac transcription factor Tbx20 and two microRNAs involved in muscle 
development, and demonstrates the importance and utility of the X. tropicalis system through 
the analysis of the conservation of four T-box genes, (8, 22, 33). 
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Cardiac transcription factors and human disease 
 In 1968, classical studies of congenital heart disease led to a hypothesis of 
multifactorial inheritance suggesting that the etiology of these cardiac defects was based on 
both genetic and environmental factors (26).  Since that time, additional environmental 
factors have been identified, however, it has become increasingly clear that there is a 
significant genetic contribution to the occurrence of congenital heart disease (16).  For this 
reason, current studies are aimed at carefully deciphering the signaling pathways that 
regulate early development and understanding how mutations in individual genes in these 
pathways lead to human pathologies such as congenital heart defects.  As described in 
Chapter 2, mutations or deletions in a number of cardiac transcription factors have been 
associated with human congenital heart defects (22).  Interestingly, of these factors, over one-
third are members of the T-box family of transcription factors.  For example, in 22q11 
deletion syndrome, which represents the most common genetic deletion syndrome in 
humans, results in part from the deletion of Tbx1.  DiGeorge syndrome is characterized by 
congenital heart defects such as tetralogy of Fallot, interruption of the aortic arch type B, 
ventricular septal defects, pulmonary atresia, or persistent truncus ateriosus (Figure 2.2)(42).  
In addition, over 30 mutations in the Tbx5 locus have been linked to Holt-Oram syndrome, 
an autosomal dominant condition characterized by upper limb defects and cardiac defects 
ranging from septal defects to tetralogy of Fallot and hypoplastic left heart syndrome (Figure 
2.2)(24).  It was not until recently, however, that nonsense and missense mutations in the 
Tbx20 locus were identified that result in a wide spectrum of developmental defects that 
includes septal, chamber and valve defects (19).  It is interesting to note that, in a study of 
352 individuals affected by congenital heart defects (CHDs), 0.6% of the patients carried a 
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mutation in the Tbx20 gene, a rate similar to that of Nkx2.5 mutations (11, 19, 23).  More 
importantly, however, approximately 5% of all individuals with a family history of CHDs 
carried Tbx20 mutations, suggesting that Tbx20 may prove to be a key target of genetic 
screening in families afflicted with CHDs (19). 
The continuing characterization of mutations and deletions in cardiac transcription 
factors and their association with a wide range of CHDs is beginning to emphasize that 
disruptions within just a single gene may lead to a vast array of defects that may or may not 
be consistent between individual patients.  On the other hand, our continued understanding of 
the interplay between factors in developmental regulatory networks suggests that disruptions 
in multiple genes may result in similar clinical presentation.  Both the diverse clinical 
presentations of patients with Tbx20 mutations and the complex phenotypes resulting from 
TBX20 knock down in mouse and frog support these ideas (6, 35, 39, 40).  For this reason, it 
will be important to identify any additional mutations within the Tbx20 locus that could be at 
the root of other clinical manifestations.  Human Tbx20 maps to chromosome 7p14, and a 
search for pathologies with similar phenotypes to Tbx20 knockdown, and that map to 
chromosome 7p14, reveals at least two potential candidates.  First, a recent study by Bhuiyan 
et al. maps an early onset lethal form of catecholaminergic polymorphic ventricular 
tachycardia (CPVT) to chromosome 7p14-22 (2).  CPVT is characterized by a reproducible 
form of ventricular tachycardia, induced by physical activity or stress, and is one of the most 
prevalent causes of sudden cardiac death in children (10, 21).  While initial analyses of the 
Tbx20 locus reveal no significant sequence variations, only coding exons and exon-intron 
boundaries were examined (2).  In a similar manner, six other cardiac genes that map to this 
region were also found to contain no sequence alterations.  It is possible that mutations in 
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regulatory regions of one or multiple gene(s) are responsible for the manifestation of this 
phenotype, leaving Tbx20 as a potential candidate.  Second, studies have demonstrated a 
requirement for TBX20 not only in cardiac development, but also in proper development of 
the nervous system, specifically of the motor neurons (37, 40).  Loss of TBX20 leads to a 
complete loss of motor function in Xenopus, and to the loss of facial, trigeminal and 
vestibuloacoustic neuronal migration in mice (5, 37).   For this reason, an investigation of 
hereditary neuropathies that map to the Tbx20 locus is also warranted.  One example is the 
inherited neuropathy axonal Charcot-Marie-Tooth disease (CMT2D), which maps to a region 
of chromosome 7p14 (12). Charcot-Marie-Tooth disease is one of the most common genetic 
diseases in humans and is characterized by a group of hereditary motor and sensory 
neuropathies (36).  For these reasons, it possible that mutations in Tbx20 could play a role in 
the manifestation of this disease, in addition to the congenital heart defects with which they 
have already been associated. 
 
Cis-regulatory modules, Tbx20 and the heart 
 As suggested above, many stages of organogenesis are controlled by a variety of 
interacting transcriptional regulatory networks.  These networks involve the precise 
expression of genes and the proteins for which they encode in a spatially and temporally 
restricted pattern.  The mechanism by which these transcriptional events are governed 
involves the interaction of transcription factors with target DNA sites that act as enhancers, 
silencers or insulators.  These DNA sites, referred to as cis-regulatory elements, typically 
cover a few hundred base pairs and contain binding sites for multiple transcription factors (1, 
14).  Interestingly, comparative analysis of the sequences of cis-regulatory systems from 
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multiple species and diverse phyla reveals that there are a number of general characteristics 
shared by all of these systems (1).  Arguably, the most striking characteristic of these 
regulatory regions is their high complexity.  Generally, in a given cis-regulatory region, 
spanning less than 500bp, binding sites for positive and negative regulators, as well as their 
co-factors are found.  A basic comparison of individual modules for a diverse array of 
developmental genes suggests that the complexity of an individual element responsible for 
the tissue-specific expression of a gene is approximately 4-8 different interactions with 
regulatory factors, and an average of five (1).  Furthermore, it appears that these factors are 
chemically diverse along any one regulatory element in that no element has been described 
that is bound by only one protein type, such as homeodomain or Zn finger proteins (1). 
 Chapter 4 describes the identification of a cardiac cis-regulatory element for the 
transcription factor Tbx20.  Briefly, a 334bp element was characterized and shown to be 
sufficient to drive the expression of Tbx20 throughout the heart at specific phase of cardiac 
development (Figure 4.3).  This element contains multiple conserved binding site sequences, 
and is bound by SMAD1, indicating that it is activated by BMP signaling (Figure 4.5-4.7).  
While this is the first step towards understanding the unique expression pattern of Tbx20 in 
the heart, and adds an additional link to the ever-growing cardiac transcriptional network, it 
is most likely only the beginning of our understanding of Tbx20 regulation.  Based on the 
comparative analyses of cis-regulatory elements across species, and on the focused 
characterization of the regulation of other cardiac transcription factors such as Nkx2.5 or 
cardiac α-actin, it is likely that Tbx20 expression involves additional factors and additional 
regulatory elements.  There are a number of attractive candidates based on expression 
patterns in the embryo, regulation of co-expressed cardiac genes, and preliminary studies.  
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One such candidate is serum response factor (SRF), a transcription factor involved in the 
regulation of a variety of muscle and cardiac genes (30).  Specifically, SRF, in combination 
with Nkx2.5, has been shown to be required for the proper regulation of cardiac genes such as 
the cardiac actin promoter (7, 25).  Additionally, conditional ablation of SRF in α-myosin 
heavy chain expressing cells results in reduced expression of cardiac genes such as atrial 
naturetic factor and cardiac, skeletal and smooth muscle α-actin (25).  Preliminary studies in 
our lab suggest that Tbx20, through the defined 334bp regulatory element, is also positively 
regulated by SRF signaling in a dose dependent manner (Figure 6.1).  This data, in addition 
to the expression of SRF in the heart, suggest that SRF is required for proper Tbx20 
expression in combination with BMP signaling.  It is also possible that another cardiac 
transcription factor, GATA4, may be involved in Tbx20 regulation.  GATA4 is a zinc finger 
transcription factor that has been shown to bind sequence specific DNA elements in the 
regulation of cardiac genes such as Nkx2.5 (3, 32).  In a similar manner to Tbx20, GATA4 is 
required for proper cardiac development and is expressed from the early stages of cardiac 
development in the two bilateral patches of migrating cardiac primordia, through adulthood, 
in the fully developed adult heart (17, 20, 29).  Sequence analysis using algorithms such as 
ConSite, TRANSFAC and JASPAR has identified multiple conserved GATA binding sites 
within the 334bp regulatory element of Tbx20.  While GATA4 fails to significantly induce 
Tbx20 expression in preliminary in vitro transcriptional assays, it is possible that it is 
required in combination with other transcription factors for the proper regulation of Tbx20 
(Figure 4.5).  For example, GATA4 has been shown to act as a mutual co-factor in the 
activation of Nkx2.5 in the heart through association with Smad1/4 on an upstream enhancer 
element (3).  From this, it will be interesting to examine the potential interactions of GATA4 
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with other proteins in the activation of Tbx20 in the heart.  Most likely, it is the combinatorial 
activity of major signaling cascades such as BMP and SRF, in addition to other regulatory 
factors such as GATA4 at precise times and locations during development, that results in the 
unique expression pattern of Tbx20 in the developing embryo. 
 
X. tropicalis as a model for studies of development and disease 
Much of our current understanding of gene regulation described both here and by 
others is a direct result of work in model systems such as Xenopus.  The utility of the 
Xenopus model in studies of early development, including cardiogenesis, has been 
appreciated and expanding since the 1950s.  Specifically, X. laevis has been well established 
and it is widely utilized in classical and molecular embryological studies.  However, a 
number of drawbacks, including its tetraploid genome and long generation time, have 
prevented its use in genetic analyses.  In light of this, the closely related X. tropicalis system 
is now emerging as a useful tool for developmental genetics.  Unlike its counterpart, X. 
tropicalis is a truly diploid species with an available annotated genome sequence (Joint 
Genome Institute), and a short generation time, lending credence to its use in genetic studies 
(34).  In Chapter 2, I describe an identification and structural analysis of four X. tropicalis 
cDNAs corresponding to Tbx1, Tbx2, Tbx5 and Tbx20, a comparison of their identity and 
similarity across species, and a complete characterization of their expression patterns in X. 
tropicalis.  Notably, these studies demonstrate the exceptional conservation of the sequence 
and expression of four key transcription factors between X. tropicalis and other vertebrate 
species.  For example, the Tbx20 sequence is greater than 97% identical between X. 
tropicalis and the well-characterized X. laevis model, and the RNA is expressed in nearly 
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identical temporal and spatial patterns in the cement gland, heart, eye and nervous system 
(33).  From this, it is evident that X. tropicalis can be utilized in concert with the established 
X. laevis system, and that we should therefore focus our efforts in a few key directions in an 
effort to make it fully applicable to studies of human disease.  First, it will be important to 
continue to work towards the optimization of forward and reverse genetic screens in X. 
tropicalis.  Forward screens have utilized multiple approaches to disrupt gene function 
including N-ethyl N-nitrosourea treatment of sperm or morpholino oligonucleotide libraries, 
and are moving towards the ability to identify novel genes that regulate development (13, 
31).  In a similar manner, a number of reverse genetic screens have utilized methods such as 
TILLING (Targeting Induced Local Lesions in Genomes) to detect mutations in specific 
genes (38).  While each of these methods has proven effective in small-scale scenarios, work 
is currently underway to achieve large-scale screening capabilities, which when reached, will 
reveal the true power of this system will be revealed.  The second focus for research groups 
utilizing X. tropicalis will be the development of Xenopus models of human disease, as 
currently there are none available.  While excellent mouse models of human disease do exist, 
X. tropicalis offers a number of distinct advantages including the accessibility of embryos 
due to external fertilization and development, and the ease and variety of available 
embryological techniques.  In the past ten years, many additional tools have become 
available for the disruption and analysis of gene function in the frog.  Utilizing techniques 
such as transgenesis, chemical mutagenesis and morpholino oligonucleotide injections that 
are widely utilized in Xenopus, efforts can be focused on the disruption of genes as they are 
identified in human disease (15, 27).  With these models, the vast potential of screens directly 
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applicable to human disease, such as large-scale drug screening, can then be fully reached, as 
current efforts have shown great promise for widespread utility (41). 
 
Future directions 
 Through the studies described in this dissertation and many others, it is becoming 
evident that the T-box transcription factor Tbx20 is an essential link in an extensive signaling 
network that controls early heart development.  This, in addition to the unique pattern of 
expression and an essential role in cardiac development, demonstrates the importance of 
gaining a more complete understanding of Tbx20 regulation and function in development.  
To this end, we currently have a number of short- and long-term goals aimed at expanding 
this knowledge.   
 
Further characterization of Tbx20 regulation 
 A major goal of this project in the immediate future is to more fully characterize 
Tbx20 regulation in the developing embryo.  The work described here characterizes a cardiac 
regulatory element that is acted upon by members of the BMP and SRF signaling pathways 
(Mandel et al., In Review).  However, this element is not sufficient for the complete 
expression of Tbx20, in that it fails to drive expression of endogenous Tbx20 in the early 
cardiac progenitor populations and nervous system (4, 33).   To address this, we have begun 
to combine a comparative genomic approach with the available transgenic techniques in 
Xenopus.  An initial comparison of the X. tropicalis Tbx20 genomic locus with that of the 
human, mouse, chick, zebrafish and Fugu loci suggests that sequence conservation is a 
feasible approach to isolate putative regulatory regions in silico.  From this, we have utilized 
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a transgenic system to identify 3 highly conserved intronic and 3’-UTR elements with ability 
to drive tissue-specific expression in the eye, brain, neural tube and rhombomeres (Figure 
6.2, Data not shown).  It will be important in the immediate future, however, to better 
characterize these putative elements and to expand this sequence analysis to extend both up- 
and downstream from the Tbx20 coding region, in an effort to identify additional factors that 
may act at a greater distance from the Tbx20 locus.  In parallel with this genomic analysis, 
we will also take advantage of the transgenic technologies available in Xenopus to identify 
distal regulatory elements or elements that may work in a combinatorial manner to drive 
Tbx20 expression.  Reporter gene expression in transgenic X. laevis can be driven by 
recombineered bacterial artificial chromosomes (BACs) in an effort to isolate transcriptional 
regulatory elements over regions as large at 300Kb (18).  A variety of Xenopus BAC libraries 
are currently available (C.H.O.R.I.), and we have identified a number of BAC clones that 
contain regions of the Tbx20 coding region (Mandel et al., In Review).  Utilizing the 
available transgenic techniques in Xenopus, it will be possible to quickly identify BACs that 
contain regions sufficient to drive specific Tbx20 expression, and in combination with 
sequence comparisons across species, to efficiently define the precise regulatory elements 
across the Tbx20 locus. 
 In addition to identifying regions within the Tbx20 locus that are involved in its 
regulation, another goal of this project is to identify signaling pathways that are responsible 
for the proper developmental expression of Tbx20.  Thus far, we have demonstrated a role for 
BMP signaling and SRF signaling in Tbx20 regulation (Mandel et al., In Review).  However, 
work to characterize the developmental regulation of other cardiac transcription factors, such 
as Nkx2.5 and Mef2c, suggests that multiple signaling pathways are required to properly 
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regulate the spatially and temporally specific expression of individual cardiac genes (3, 9).  
To address this question for Tbx20, it will be possible to utilize a yeast one-hybrid approach 
to screen a Xenopus cardiac-specific cDNA library with the minimal Tbx20 cardiac 
regulatory element.  For this, we have created both cardiac-specific and embryo minus heart-
specific X. tropicalis cDNA libraries from both stage 17 (tailbud) and stage 46 (tadpole) 
embryos (E.M.M., unpublished data).  We will now utilize a modified linker scanning 
mutagenesis approach to identify the minimal regulatory element of Tbx20 that is necessary 
for its expression in the heart.  This element will then be used to screen the cardiac specific 
cDNA libraries to identify any other proteins that directly interact with the Tbx20 regulatory 
element, thus giving us insight into any additional signaling pathways that may be involved 
in proper Tbx20 expression.  Additionally, the availability of this technique and the 
establishment of this system for use with Xenopus cDNA libraries and Tbx20 will allow for 
the identification of signaling factors that interact with additional regulatory elements as they 
are identified, thus expanding our understanding of regulated gene expression during 
development. 
 
Identification of downstream TBX20 targets 
 While the immediate goals of this project focus on the identification of upstream 
regulatory factors of Tbx20, it will also be necessary, in the longer term, to identify the 
downstream targets of TBX20 in order to piece together a complete transcriptional regulatory 
network.  To date, TBX20 has been suggested to act upstream of a small number of cardiac 
and neural factors, including Tbx2, Isl2, and Hb9 (35, 39, 40).  However, given its 
requirement for proper heart and neural development, we hypothesize that TBX20 is 
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involved in the proper regulation of a wide panel of cardiac and neural factors.  To identify 
additional downstream targets of TBX20, we will proceed with two parallel approaches, both 
of which take advantage of morpholino oligonucleotide knock down of TBX20, a technique 
which has been previously described in Xenopus (5).  First, we will take a candidate-based 
approach by which we will examine differences in the expression patterns of candidate genes 
between wildtype embryos and those depleted of TBX20 expression.  Preliminary work in 
the neural tube demonstrates that TBX20 loss leads to an expansion of the motor neuron 
marker, MNR2, and a reduction of the interneuron marker, EN1, suggesting that TBX20 may 
lie upstream of these factors (Figure 6.3; E.M.M., unpublished data).  In parallel, we will 
utilize a microarray approach to identify genes that are differentially regulated upon knock 
down of TBX20.  RNA will be isolated from wildtype or TBX20-depleted tissue (heart or 
neural tube) to screen the currently available Xenopus microarray chips (Affymetrix).  
Similar methods have proven to be efficient and effective for the identification of target 
genes in Xenopus, and will likely prove effective in our efforts to place TBX20 within a large 
transcriptional regulatory network (28). 
 
Closing remarks 
 The work described within this dissertation represents a significant advance in our 
understanding of the signaling mechanisms and early events of cardiac development.  
Specifically, this work focuses on the T-box transcription factor Tbx20, and its expression, 
function and regulation in the developing heart.  By defining the mechanisms of 
transcriptional regulation of individual cardiac factors that have been shown to be required at 
early stages of development, we can further our understanding of the molecular program that 
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regulates early organogenesis.  Additionally, a further understanding of specific regulatory 
systems will not only provide insight in to the inner workings of individual signaling events, 
but will also indicated the specific interconnections between signaling cascades.  Such 
studies are imperative to the field of cardiovascular biology in that alterations of early 
signaling events have been shown to underlie the manifestation of many human congenital 
diseases, and pose as a significant threat of human mortality.  It is our hope that the work 
described herein provides useful insight into the unknown signaling events involved in early 
cardiogenesis and may eventually advance our understanding of human disease. 
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Figure 6.1.  A 334bp 5’ regulatory element of Tbx20 is activated by SRF signaling.  A 
luciferase reporter controlled by a 334bp 5’ regulatory element is activated by increasing 
doses of SRF when co-transfected into COS7 cells as previously described (see chapter 4).  
Fold induction reflects changes in induction relative to induction of the reporter alone.  Error 
bars represent standard error of 3 replicates. 
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Figure 6.2.  Evolutionarily conserved sequences drive tissue-specific expression of 
Tbx20.  A, VISTA alignment and conservation between X. tropicalis and H. sapien Tbx20.  
Peaks represent the level of conservation between species using a 100bp window.  Blue 
peaks denote coding sequence, while red peaks represent conservation of non-coding regions.  
The upper line represents a threshold of 63% conservation.  The 2464bp cardiac regulatory 
element described in chapter 4 is boxed in green, while 3 putative regulatory elements are 
boxed in red.  B, Schematic representation of the Tbx20 locus and the location of 3 tissue-
specific regulatory elements as determined by a transgenic analysis in X. laevis.  The eight 
exons are represented by solid black boxes with the base pair length noted.  Wavy lines 
represent non-coding sequences. 
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Figure 6.3.  TBX20 knock down leads to changes in EN1 and MNR2 expression.  
Morpholino oligonucleotides (MO) against Tbx20 were injected into single cell embryos as 
previously described to block translation of TBX20 (5).  Wildtype and MO-injected embryos 
were fixed and sectioned for immunohistochemistry at stage 35 (see chapter 4) using α-EN-1 
and α-Mnr2 primary antibodies (Developmental Studies Hybridoma Bank) and an α-mouse-
cy3 secondary antibody.  A-B, EN-1 expression marks a subset of interneurons at the lateral 
edge of the neural tube (arrowheads) in wildtype (A) and MO-injected (B) embryos.  C-D, 
Mnr2 is expressed in the floor plate (fp), notochord (nc) and hypochord (hc) of wildtype (C) 
and MO-injected (D) embryos. 
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